Molekulare Charakterisierung von NFAT-Transkriptionsfaktoren in experimentellen Mausmodellen by Alrefai, Hani Gouda Alsaid
Molecular Characterization of NFAT Transcription
Factors in Experimental Mouse Models
Molekulare Charakterisierung von NFAT-Transkriptionsfaktoren
in experimentellen Mausmodellen
PhD thesis submitted as a partial fulfillment of requirements for the PhD degree at the Graduate School of Life
Sciences, Julius-Maximilians- Universität Würzburg,
Section Infection and Immunity
Submitted by
Hani Gouda Alsaid Alrefai
from
El-Mansoura, Egypt
Würzburg, 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Gedruckt mit Unterstutzung des Deutschen Akademischen Austauschdienstes“ 
 
Submitted on: …………………………………………………………..……..
Office stamp
Members of the Promotionskomitee:
Chairperson:
Primary Supervisor: Prof. Dr. Edgar Serfling
Supervisor (Second): Prof. Dr. T. Müller
Supervisor (Third): Prof. Dr. A. Müller
Date of Public Defence:
Date of receipt of Certificates:
Affidavit
I hereby declare that my thesis entitled “Molecular Characterization of NFAT Transcription
Factors in Experimental Mouse Models” is the result of my own work. I did not receive any help
or support from commercial consultants. All sources and / or materials applied are listed and
specified in the thesis.
Furthermore, I verify that this thesis has not yet been submitted as part of another examination
process neither in identical nor in similar form.
Würzburg……………………………………………………………………
Date Signature
Eidesstattliche Erklärung
Hiermit erkläre ich an Eides statt, die Dissertation „Molekulare Charakterisierung von NFAT-
Transkriptionsfaktoren in experimentellen Mausmodellen“ eigenständig, d.h. insbesondere
selbstständig und ohne Hilfe eines kommerziellen. Promotionsberaters, angefertigt und keine
anderen als die von mir angegebenen Quellen und Hilfsmittel verwendet zu haben.
Ich erkläre außerdem, dass die Dissertation weder in gleicher noch in ähnlicher Form bereits in
einem anderen Prüfungsverfahren vorgelegen hat.
Würzburg……………………………………………………………………
Datum Unterschrift
“Among Allah's worshipers, those who have the most knowledge, fear him the most"
Surat Fater, Vers 28, The Holly Qurraan.
Acknowledgments
I would like to thank my supervisor, Prof. Dr. Edgar Serfling, for his advice and guidance.
His availability at all time made it possible to go through my work, knowing that he got my back.
I enjoyed working with him side by side on the bench. His famous question –with a full
smile on his face- ‘Why not do it today?’, kept me running and was needed to get me
where I am standing today. I would also like to thank my other supervisors, Prof. Dr. T. Müller
and Prof. Dr. A. Müller for their valuable time and input. I am much obliged to Prof. Dr. Thomas
Hünig for the excellent learning experience he provides in the graduate college GK520
“Immunomodulation” I am grateful to all the GSLS members, especially Gabriele, Bianca,
Jennifer, Susanne and Rose for their friendly help and support.
I am very grateful to Doris and Ilona for their help with the cells and mice. I
would like to thank Rhoda,  Ron and Amiya, for introducing me to FACS. I cannot forget to
acknowledge Jolly and Sankar for taking my hand into establishing my own WB protocol. I thank
Khaled for his help and support. I would like to thank Stefan for his advice on EMSA and helping
me with the ‘Zusammenfassung’. I thank Andris for his continuous support in primer design.  I
enjoyed my scientific and social talks with Martin and for  this  I am thankful  to  him. I
want  to  ex tend my regards  to Rike, Lena, Tobi and Duong for being there as a pushing
force. It would have been more difficult for me without Angelika, our department secretary,
helping me in all the formal paper work. I sincerely thank Dr. Puppe –for IT support-, Mr.
Ralf –for Immunohistochemistry support- and Mr. Schmitt –for his lovely clear pictures-.
I am very much indebted to the Egypt ian government  and DAAD (Egypt and
Germany teams) for providing the funds and the support that gave me the chance to conduct
my PhD studies in Germany.
No words can describe my deep gratitude to Shereen, my wife. Her endless caring carried
me every step of the way and whom without I could never had came this far. I thank my children:
Ahmed, Hesham and Malak for always painting a smile on my heart.
Most of all, I would like to acknowledge my debt to my parents. Their vision and love
always paved the way and their prayers blessed my life.
Contents
1. Introduction......................................................................................................................................... 1
1.1. Nuclear factors of activated T lymphocytes (NFATs)........................................................................ 3
1.2. NF-κBs................................................................................................................................................ 7
1.3. B cells ............................................................................................................................................... 10
1.4. Psoriasis ............................................................................................................................................ 13
2. Aim of the Work................................................................................................................................ 20
3. Material and Methods ...................................................................................................................... 21
4. Results ................................................................................................................................................ 45
4.1. Expression of a constitutive active version of NFATc1 (caNFATc1/αA) with ablated IRF4 in B cells
from mice. ................................................................................................................................................... 45
4.2. The NFAT - NF-κB connection........................................................................................................ 49
4.3. IMQ- induced skin inflammation - a mouse model for human psoriasis ......................................... 56
5. Discussion........................................................................................................................................... 64
5.1. Expression of a constitutive active version of NFATc1 (caNFATc1/αA) with ablated IRF4 in B cells
from mice. ................................................................................................................................................... 64
5.2. The NFAT - NF-κB connection........................................................................................................ 65
5.3. IMQ- induced skin inflammation - a mouse model for human psoriasis ......................................... 69
6. References .......................................................................................................................................... 73
List of Figures:
1.1. NFAT family members................................................................................................................... 3
1.2. NFAT Activation cascade .............................................................................................................. 5
1.3. Illustration of the Nfatc1 gene and its expression products............................................................ 6
1.4. NF-κB family members .................................................................................................................. 7
1.5. Pathways leading to the activation of NF-κB ................................................................................. 8
1.6. Stages of B cell development. ...................................................................................................... 11
1.7. The germinal center. ..................................................................................................................... 12
1.8. Normal skin .................................................................................................................................. 14
1.9. Clinical patterns of Psoriasis. ....................................................................................................... 16
1.10. Immunological events in psoriasis…………...…………………………………………… …...18
4.1. Expression of NFATc1 in splenic B-cells from caNFATc1/αA x mb1cre mice .......................... 45
4.2. Lymphocytic counts using Flow cytometry. ................................................................................ 46
4.3. Activation Induced Cell Death (AICD) of splenic B-cells from caNFATc1/αA x IRF4f/f x mb1cre
and IRF4f/f x mb1cre mice, after 48 hour incubation.................................................................... 47
4.4. Proliferation studies of splenic B-cells from caNFATc1/αA x IRF4f/f x mb1cre and IRF4f/f x
mb1cre .......................................................................................................................................... 48
4.5. Expression of Rel-B in B-cells from IRF4Ko. ............................................................................. 49
4.6. Activation Induced Cell Death (AICD) in splenic B-cells after incubation for 48 hours in c-
RelKo mice. .................................................................................................................................. 50
4.7. Proliferation studies of splenic B-cells deficient for NFATc1 , c-Rel or both factors (DKO). .... 51
4.8. Expression of Rel-B in B-cells from NFATc1f/f x CD23cre, caNFATc1 xCD23cre and
caNFATc1 x NFATc1f/f x CD23cre mice..................................................................................... 52
4.9. Expression of NFATc1 in B cells from c-Rel Knock-out mice.................................................... 53
4.10. EMSA and super shift EMSA for detecting NFAT and NF-κB factors in primary splenic B cells
from wild type and c-Rel-deficient mice ...................................................................................... 54
4.11. RT-PCR assay showing the generation of NFATc1 RNA from p1 in primary splenic B cells from
wild type and c-Rel-deficient mice............................................................................................... 55
4.12. Plasma cells in c-Rel Ko mice. ..................................................................................................... 56
4.13. IMQ-induced psoriasis-like inflammation in WT mice................................................................ 57
4.14. IMQ induced psoriasis-like inflammation in WT and NFATc1f/f x mb1cre mice........................ 58
4.15. IMQ induced psoriasis-like inflammation in mice bearing two inactivated mb1/Cd79a alleles
(mb1cre homozygous) .................................................................................................................. 60
4.16. IgG1 expressing B cells from LN in IMQ induced psoriasis-like inflammation.......................... 61
4.17. Bregs in LN in IMQ-induced psoriasis-like inflammation........................................................... 62
4.18. IL-10 expression from Bregs in LN in IMQ induced psoriasis-like inflammation. ..................... 63
Summary 1
Summary
In this work we wanted to investigate the role of NFATc1 in lymphocyte physiology
and in pathological conditions (eg. psoriasis). NFATc1 is part of the signal transduction
pathways that regulates B cells activation and function. NFATc1 has different isoforms that are
due to different promoters (P1 and P2), polyadenylation and alternative splicing. Moreover, we
tried to elucidate the points of interactions between the NFAT and the NF-κB pathways in
activated B-cell fate. NFAT and NF-κB factors share several properties, such as a similar mode
of induction and architecture in their DNA binding domain. We used mice which over-express a
constitutive active version of NFATc1/α in their B cells with -or without- an ablated IRF4. IRF4
inhibits cell cycle progression of germinal center B cell-derived Burkitt’s lymphoma cells and
induces terminal differentiation toward plasma cells. Our experiments showed that a ‘double
hit’ in factors affecting B cell activation (NFATc1 in this case) and late B cell differentiation
(IRF4 in this case) alter the development of the B cells, lead to increase in their numbers and
increase in stimulation induced proliferation. Therefore, the overall picture indicates a link
between these 2 genes and probable carcinogenic alterations that may occur in B cells.
We also show that in splenic B cells, c-Rel (of the NF-κB canonical pathway) support
the induction of NFATc1/αA through BCR signals. We also found evidence that the lack of
NFATc1 affects the expression of Rel-B (of the NF-κB non-canonical pathway). These data
suggest a tight interplay between NFATc1 and NF-κB in B cells, influencing the competence of
B cells and their functions in peripheral tissues.
We also used IMQ-induced psoriasis-like inflammation on mice which either lack
NFATc1 from B cell. Psoriasis is a systemic chronic immunological disease characterized
primarily by abnormal accelerated proliferation of the skin keratinocytes. In psoriasis, the
precipitating event leads to immune cell activation. Our experiments showed that NFATc1 is
needed for the development of psoriasis. It also showed that IL-10 is the link that enables NFAT
from altering the B cell compartment (eg Bregs) in order to affect inflammation. The important
role of B cell in psoriasis is supported by the flared up psoriasis-like inflammation in mice that
lack B cells. Bregs is a special type of B cells that regulate other B cells and T cells; tuning the
immunological response through immunomodulatory cytokines.
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Zusammenfassung
Diese Arbeit befasst sich mit der Regulation und der Funktion des Transkriptionsfaktors
NFATc1 (“nuclear factor of activated T-cells c1) in B-Lymphozyten. Hierzu wurde zum einen
die transkriptionelle Kontrolle des Nfatc1-Gens in aktivierten B-Lymphozyten und zum anderen
die Bedeutung dieses Faktors für die Wachstumskontrolle und Autoimmunität anhand
verschiedener Modellsysteme analysiert.
Sechs verschiedene NFATc1-Isoformen können in B-Lymphozyten durch die Nutzung zweier
verschiedener Promotoren, zweier Polyadenylierungsstellen und eines alternativen Splicings
generiert werden. Wir zeigen hier, dass insbesondere die NF-kB Faktoren c-Rel und p50 eine
essentielle Bedeutung für die starke Induktion des Promoters P1 und damit der Expression der
kurzen Isoform NFATc1A in B-Zell-Rezeptor-stimulierten B-Zellen spielen.
Interessanterweise zeigen NFATc1-defiziente B-Lymphozyten eine geschwächte Aktivierung
der NF-kB-Faktoren, was auf eine enge Verknüpfung dieser zwei Signalwege hindeutet.
NFATc1-defiziente B-Lymphozyten weisen eine Aktivierungs- und Wachstumsschwäche auf
(Bhattacharyya S., et.al.). Hier zeigen wir, dass die Überexpression von konstitutiv aktivem
NFATc1A in B-Lymphozyten, insbesondere wenn dies im Kontext einer IRF4-Defizienz
geschieht, zu einer verstärkten Expansion der B-Zellpopulation, insbesondere nach deren
Aktivierung, führt. Dies belegt die kritische Bedeutung, die der wohldosierten Expressions- und
Aktivierungskontrolle der NFATc1-Faktoren in B-Lymphozyten zukommt.
Dies zeigt sich auch in einem Imiquimod-induziertem Psoriasis Mausmodell. Hier wird
durch Applikation von Imiquimod auf die Haut eine der Schuppenflechte ähnelnde entzündliche
Reaktion ausgelöst, die insbesondere durch eine stark verstärkte Proliferation der Keratinozyten
gekennzeichnet ist.  Wir können zeigen, dass die NFATc1-Faktoren in B-Lymphozyten kritisch
an dieser Reaktion beteiligt sind. Fehlt den B-Lymphozyten das NFATc1-Gen, so produziert
eine Subpopulation, die sogenannten regulatorischen B-Zellen, verstärkt das
immunmodulatorischen Zytokins IL-10, wodurch die entzündliche Reaktion fast komplett
unterdrückt wird. Dies ähnelt vorhergehenden Beobachtungen, in denen wir zeigen konnten,
dass auch in einem Mausmodell der Multiplen Sklerose (EAE) die Immunreaktion durch den
Verlust von NFATc1 in B-Zellen erheblich gelindert werden kann (Bhattacharyya S., et.al.).
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1. Introduction
1.1.Nuclear factors of activated T lymphocytes (NFATs)
1.1.1. Family and structure
The name of NFAT comes from its first discovery in T cells as a transcription factor
(TF) that binds to the IL-2 DNA promoter region following the activation  of the TCR
(Serfling et al., 1989; Shaw et al., 1988). This name was sustained, although, studies have
shown that this TF family is expressed in many cell types other than T cells. NFAT gained
more interest after discovering that it is negatively regulated by Cyclosporin A (CsA). At
that time, CsA was the new "dream drug" for improvement of transplantation medicine as
an immune suppressor against organ rejection. The identification of the NFAT family and
their isoforms was followed giving rise to 5 NFAT members, but only 4 of them are
considered typical and are part of the Ca-Calcineurin pathway (NFATc1, c2, c3 and c4).
NFATc5 is regulated by osmotic stress and is considered a kind of evolutionary link
between the NFAT family and the NF-кB family. The typical NFAT members have
different isoforms that come from different promoters (P1 and P2), polyadenylation and
alternative splicing, differing in the C or/and N terminals. The Rel-Similarity domain (RSD)
is the DNA binding domain and its name comes from its similarity to the DNA binding site
in the older NF-кB family. The NFAT similarity Domain (NSD) contains the regulatory
domain (REG) that is rich of serine residues. There is about 70% similarity in the RSD
among the typical NFAT members that falls to only 40% with the NFATc5. NFATc5 lacks
the REG domain (Chen et al., 1998; Chuvpilo et al., 1999; Lopez-Rodriguez et al., 1999).
Figure 1.1: NFAT family members.
All five NFAT family members are shown with their different structures. NFATc1 is shown
with its diffrent isoforms. Ca2+-dependent regulatory domain (REG) is in violet. The
highly conserved Rel-similarity domain ,RSD, is in yellow. The transactivation domains
(TADs) are  marked in red. Brown ellipses mark the serine-pro(SP) 1-3 motifs. Nuclear
localization signal (NLS) domains are in green. Nuclear export signal (NES) domains are in
white. Modified from (Serfling et al., 2006b).
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1.1.2. Activation
At the basal state, NFAT factors are located in an inactive form in the cytoplasm.
The rise of the intracellular calcium  is the corner stone of the NFAT activation cascade.
The engagement of the BCR or TCR or other surface receptors in the immune cells (eg. Toll
like receptors (TLR)) leads to activation of the phospholipase C (PLC) enzymes (eg. PLCγ).
PLC cleaves phosphoinositoidbiphospate (PIP2) into diacylglycerol (DAG) and
inositoltriphosphate (IP3). IP3 binds to its specific receptors in the endoplasmic reticulum
(ER) leading to release of the intracellular calcium stores. The depletion of these stores
stimulates ER stromal interaction molecules  (STIM1 & STIM2) which induce a
conformational change in the calcium-release activated calcium channels (CRAC) protein
Orai1, opening of the channel and leading to influx of calcium from the extracellular
compartment (Hogan et al., 2010). Calcium binds to calmodulin, then the Ca++/calmodulin
complex activates calcineurin (serine/threonine specific phosphatase).
Activation of calcineurin is rate-limiting for NFAT activation in all cells.
Calcineurin dephosphorylates the serine pro motifs (SP) that are mainly located in the REG
domain (18 out of the 20 identified), exposing the NLS domain leading to nuclear transfer
of the NFAT.  NFAT bind to specific DNA sequence and promote transcription in
association with other transcription factors. When Calcineurin is inhibited , nuclear kinases
re-phosphorylate NFAT leading to its transfer back to the cytoplasm. Different scaffold
proteins have been shown to interact with NFAT proteins and to be involved in the
regulation of their activity (Li et al., 2011).
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Figure 1.2: NFAT Activation cascade
Immunoreceptors and receptor tyrosine kinases (RTKs) bind to their ligands and activate the phospholipase
Cγ (PLCγ). Inositol-1,4,5-trisphosphate (InsP3) binds to the InsPR on the endoplasmic reticulum (ER)
membrane and induces the efflux of Ca++. Stromal interaction molecules (STIMs) communicate with the
calcium-release activated calcium (CRAC) channel protein ORAI in the plasma membrane. Ca++ binds to
the calcium sensor protein calmodulin, which in turn activates calcineurin. Calcineurin dephosphorylates
and activates NFAT transcription factors, which then translocate to the nucleus, where they can cooperate
with multiple transcriptional partners (for example, activator protein 1 (AP1)) to regulate gene expression.
NFAT proteins are rephosphorylated and inactivated by multiple NFAT kinases. Adapted from (Muller and
Rao, 2010).
1.1.3. Genetics of NFATc1
The murine and human NFATc1 genes are highly conserved. The NFATc1 genes
span 110-140kb long, extending over 11 exons. The transcription of Nfatc1 genes are
controlled by two different promoters (P1 and P2). The P1 promoter is an inducible
promoter that comes in action with engagement of the immune receptors (e.g. TCR, BCR
…etc.). The P2 promoter is a constitutively active promoter that is serving under resting
conditions. The products of these two promoters are further processed by  alternative
splicing and polyadenylation machinery  giving six known different isoforms with
individual functions (Serfling et al., 2012). Specific for the NFATc1/A, is the autoregulation
that is exhibited by the binding of the NFAT factors to the κB/NFAT site (at position −720
within the distal homology of P1) and NFAT−90 (within the proximal P1 promoter region).
It was suggested that binding of the NFATc1 to this site produces positive regulatory effects
while binding of the NFATc2 produces a negative regulatory effect on NFATc1/αA
expression (Chuvpilo et al., 2002).
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Figure 1.3: Illustration of the Nfatc1 gene and its expression products
The transcription of Nfatc1 is directed by two alternative promoters, the inducible P1 promoter and the
relatively constitutive P2 promoter, which together with alternative splicing and polyadenylation events
are giving rise to six known different isoforms. pA1 is a weak polyadenylation site, which is used to
terminate the short isoforms α/A and β/A. pA2 is a strong polyadenylation site, which is used to
terminate the long isoforms B and C. Based on (Chuvpilo et al., 2002).
1.1.4. Functions
NFATc1 and NFATc2 regulates FOXP3 expression in iTReg cells by binding
regulatory elements in the Foxp3 gene (Zheng et al., 2010). Constitutive NFATc1 is
important to sustain the expression of IL-17A in CD4+ T cells (Gomez-Rodriguez et al.,
2009).  NFATc2 is preferentially required for CD8 peripheral tolerance, although it is not
required for CD4 tolerance or their regulatory effect on CD8 T cells functions (Fehr et al.,
2010). NFATc1 is one of the prerequisites for the B-1a cells development (Berland and
Wortis, 2003). NFATc1 is part of the signal transduction pathways that regulates B cells
activation and function (Haylett et al., 2009; Winslow et al., 2006). NFATc2 is important
for the function of dendritic cells (DCs) and megakaryocytes (Crist et al., 2008; Zanoni et
al., 2009). NFATs are essential in the development of muscles (cardiac , skeletal and
smooth) nervous system, vascular system , skeleton and skin (Hogan et al., 2003; Horsley et
al., 2008; Negishi-Koga and Takayanagi, 2009).
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1.2.NF-κBs
1.2.1. Family and structure
The first description of this family of TFs was for B cells (Sen and Baltimore, 1986).
The family members are the Rel proteins: RelA (p65), RelB, c-Rel and NF-κB1(p50) and
NF-κB2(p52). The  p50 and the p52 proteins are the processing products of the p105 and
p100 precursor proteins respectively. This activation is mediated by the
ubiquitin/proteasome pathway (Nabel and Verma, 1993). The NF-κB factors are present in a
functional dimeric unit which maybe a homodimeric or a heterodimeric complex. All NF-
κB members can form homodimers, except RelB (Ghosh et al., 1998). The most common
pairs of active NF-κB are RelA-p50 (canonical pathway) and RelB-p52 (non canonical
pathway). All five NF-κB proteins contain the Rel homology domain (RHD) which is
responsible for DNA binding, dimerization and nuclear translocation. The RHD spans 300-
amino-acids and is highly conserved. The Rel family members also contain a transactivation
domain that is responsible for the activation of  promoters and enhancers of numerous other
genes (Li and Verma, 2002).
Figure 1.4: NF-κB family members
Schematic representation of members of NF-
κB family. The processing sites for p100 and
p105 are also indicated by an arrow. The
numbers of amino acids spanning each
protein are listed on the right. The
abbreviations used are: RHD, rel homology
domain; TAD, transactivation domain; NLS,
nuclear localization sequences; NES, nuclear
export sequences; DD, death domain, also
dubbed as PID, processing inhibitory domain;
LZ, leucine zipper adapted from (Xiao et al.,
2006).
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1.2.2. Activation
Figure 1.5: Pathways leading to the activation of NF-κB
The figure illustrates the different activation pathways for NF-κB in response to different stimuli.
The canonical (atypical and typical) and non canonical pathways are shown. Abbreviations: Ac,
acetylation; bZIP, leucinezipper-containing transcription factor; HMG-I, high-mobility-group
protein-I; IκB, inhibitor of κB; IKK, IκB kinase; LMP1, latent membrane protein-1; LPS,
lipopolysaccharide; NF-κB, nuclear factor-κB; RHD, Rel-homology domain; TAD, transcriptional
activation domain; TF, transcription  factor; UV, ultraviolet; Zn-finger TF, zinc-finger-containing
transcription factor. Adapted from: (Perkins, 2007)
The most common activation pathway of NF-κB is the canonical pathway. This is
due to the fact that it can be induced through different external stimuli and receptors leading
to highly variable forms of NF-κB subunits with various functions. The typical activation is
IKK dependent and starts by TNFα, TCR, BCR or TLRs. These receptors when engaged
lead to activation of NEMO (NF-κB essential modifier) in the IKK complex and causes
phosphorylation of the IκBα at Ser23 and Ser36 and their subsequent ubiquitylation and
degradation. At the end several forms of the NF-κB dimers are formed based on the
contribution of all NF-κB members (Perkins, 2006).
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Another atypical, though IKK dependent, activation of the canonical pathway is that
in response to genotoxic stress. NEMO is shuttled into the nucleus and is sumoylated and
then ubiquitylated under the control of the ataxia telangiectasia mutated  checkpoint kinase
(ATM). After that, the NEMO-ATM complex is shuttled back to the cytoplasm where it
activates the IKK complex. The atypical IKK independent pathways relies on two players to
induce the degradation of IκBα: CK2 (casein kinase-II) and TyrK (tyrosine dependent
kinase) (Krappmann and Scheidereit, 2005). The non-canonical pathway is stimulated
through CD40 ligands, TLRs, lymphotoxin receptors and others. These stimuli leads to
activation of the IKKα through NIK (NF-κB inducing kinase). The active IKKα leads to
26S proteosome-mediated modification of p100. At the end the active p52-RelB dimmer is
formed which binds to distinct κB DNA motifs (Moorthy et al., 2006).
1.2.3. Function and dysfunction
The NF-κB family is widely distributed in many cells of the body. Studies have
shown that they are important for embryogenesis and normal development of tissues
(Carrasco et al., 1994). They control and share in regulating many fundamental processes
of the body; as cell survival, cell proliferation, immunity (adaptive and innate) and memory
(Lai et al., 2010; Mao et al., 2009). Also, they act as mediators of cellular responses against
stress of different nature: chemical (eg. free radicals), physical (UV) and biological stress
(bacteria and virus) (Kim et al., 2008; Murley et al., 2001; Muthusamy and Piva, 2010).
The NF-κB pathway is integrated into other signal transmission pathways in the cell and
performs many interactions to finely tune cell homeostasis. Cell survival is moderated by
fine tuning the activity of the NF-κB versus the JNK pathway (Resch et al., 2009). Cell
response to genotoxicity is a product of cross talk between the NF-κB and the p53
pathways (Heyne et al., 2013). Hormonal mechanisms of action are affected by
collobaration of the NF-κB pathway with nuclear receptors (Greene et al., 2010). In B cells,
NF-κB mediate signals initiated through the BCR that contribute to their final stages of
maturity as well as early developmental stages (Balkhi et al., 2012). Therefore, its easily
predictable that dysfunction of the NF-κB pathway leads to severe defects in B cell
development and to B cell oncogenesis (Staudt, 2010).
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1.3.B cells
1.3.1. B cells development and activation
The development of B cells starts in fetal life in the fetal liver. It continues postnatal
in the bone marrow and peripheral lymphoid organs (PLO), like the lymph nodes (LN) and
spleen (LeBien, 2000). The B cells pass through two main stages of development: antigen-
independent (Pro B cell, Pre B cell, immature B cell and naïve B cell; in the BM) and
antigen-dependent (B cell activation, Memory B cell and plasma B cell; in the PLO)
(LeBien and Tedder, 2008). In the antigen-independent stage the B cell repertoire is built by
V(D)J rearrangement. B cells from this stage can react against virtually any possible antigen
that they could encounter and that is why they need to be re-tuned by central tolerance to
avoid auto reactivity. The central tolerance is achieved by B cell receptor (BCR) editing and
clonal deletion (Menard et al., 2013).
The B cell leaves the BM and travel to the PLO through the blood where it reaches
maturity and expresses IgD too. It is then faces the second Check-point for auto reactivity
where failed cells are eliminated by apoptosis or anergy (Isnardi et al., 2008). B cell
activation may occur as a result of interaction with T cells (T cell dependent activation) or
in absence of any signals from T cells (T cell independent activation). In the T cell
dependent activation, the B cells encounter the antigen peripherally then migrate to the PLO
where they interact with T cells that were exposed to the same antigen and the
immunological synapse results in a full blown B cell differentiation cascade specific for this
antigen. In T cell independent activation the secondary activation may come from TLR
(Type 1) or from a multivalent binding of BCR, that could happen with some bacterial
carbohydrate antigens (Type 2) (Briney and Jr, 2013).
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Figure 1.6: Stages of B cell development.
Diagram of B lineage development from hematopoietic stem cells (HSC) in mouse bone marrow through
multilineage progenitor (MLP) and common lymphoid progenitor (CLP) to B cell committed stages showing
cell surface phenotype, expression of B-lineage genes and of mu heavy chain and kappa light chain. Based on
(Hardy and Hayakawa, 2001).
1.3.2. B cell types
B cells could be classified according to their role in immunity into B1 and B2. B1
cells are part of the innate immune system. They are less common, do not form memory
cells and found mainly in the serous cavities like the peritoneum and the pleura (Ghosh et
al., 2012). B2 cells are the more common type, sharing in adaptive immunity through their
high diversity coming from their ability to undergo somatic hyper-mutation and class
switching. B2 cells are found mainly in the peripheral lymphoid organs and can be
differentiated mainly from B1 cells by lack of surface expression of CD5 and the higher
expression of IgD, IgG and IgA (Suzuki et al., 2010).
The germinal centers of peripheral lymphoid organs are the site of the T cell
dependent B cell activation. They are delineated into dark and light zones. In the PLO two
distinct populations of B cells could be recognized. The Follicular B cells (FO) which is the
dominant population (95%) with a CD23hi CD21low pattern (McHeyzer-Williams and
McHeyzer-Williams, 2005). They are freely circulating with a higher stimulation threshold.
On the other hand, the marginal zone B cells (MZ) are a small population of residential B
cells characterized by their CD23low CD21hi pattern (Pillai et al., 2005).
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Figure 1.7: The germinal center.
B cells activated by antigens are transformed to centroblasts. These centroplast prolifrate , expand and undergo
somatic hypermutation (SHM). The centroblasts moves into the light zone and transform to centrocytes. T
cells and follicular dendritic cells (FDCs) select the most competent of the centrocytes which differentiate into
memory B cells or plasma cells, while the centrocytes that have an unfavourable antibody are deleted by
apoptosis. Adapted from (Klein and Dalla-Favera, 2008)
1.3.3. B cell functions
B cells share directly in the immune response by differentiating into Ag-specific
antibody producing cells (plasma cells) (LeBien and Tedder, 2008). They become part of
the memory immune response because they also differentiate to memory B cells which
ensures a more efficient and faster secondary immune response (Price and Luftig, 2014).
They can indirectly share in the immune reaction either positively by serving as a
professional antigen presenting cells to CD8+ T cells or negatively through producing IL-10
(DiLillo et al., 2010; Salerno-Goncalves et al., 2014). Moreover, B cells serve as a co-
activator of T cells during immune response through CD80, CD86 and OX40L interactions
(O'Neill et al., 2007).
1.3.4. Regulatory B cells (Bregs)
Bregs are one of the newly introduced subtypes of B2 cells. They are a small
population of CD5+CD1dhi B cells that are able to express and excrete IL-10 when
stimulated (Yanaba et al., 2008). The development of these Tregs are dependent on BCR,
TLR and CD22 signals (Tedder et al., 2005). They are believed to have a regulating
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influence on other B cells and T cells; tuning the immunological response in a concept
similar to Tregs but exploiting other immunomodulatory cytokines (Yanaba et al., 2009).
They serve to keep the immune response in check in case of auto immune diseases and in
case of fulminate inflammatory conditions. Their effects are reported on Th1, Th17, CD4+ T
cells and Monocytes (Mauri and Bosma, 2012).
1.3.5. Role of interferon regulatory factor 4 (IRF4) in B-cell development
IRF4 plays a critical and non-redundant role in the adaptive immune responses of
mature B cells. Without IRF4, mature B cells accumulate in increased numbers in the spleen
and lymph node, although there is a quantitative defect in the percentage of IgMhi, IgDlo,
CD23lo mature B cells (Shaffer et al., 2009).
IRF4 is up-modulated by CD40 engagement, and down-modulated by apoptotic and
anti-proliferative signals, suggesting involvement of IRF4 in Hodgkin lymphoma
pathobiology (Aldinucci et al., 2010).
IRF4 inhibits cell cycle progression of germinal center B cell-derived Burkitt’s
lymphoma cells and induces terminal differentiation toward plasma cells through
mechanisms independent of BCL6 downregulation (Teng et al., 2007).
1.4.Psoriasis
1.4.1. Burden of Psoriasis
The area of the skin is about 1.8 square meters in total making it the largest organ of
the human body. It is part of the immune system and considered as the first line of
protection against microbes and foreign agents. It consists of two main layers: the epidermis
(the upper layer) and the dermis (the lower layer). The hypodermis may refer to a third layer
of of subcutaneous fat and connective tissue lying even deeper to the previous layers.
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Figure 1.8: Normal skin
The normal skin of human consists of two main layers. The epidermis is the upper layer of the skin and
it consists mainly of keratinocytes. The basal layer of epidermis is the one responsible of division and
regeneration of all the upper cells. The spinous layer lies above the basal layer. Keratinocytes in the
spinous layer are polygonal and held together by desmosomes. The granular layer is the last living layer
of the keratinocytes lying above the spinous layer and below cornified layer. It is a thin layer of cells
that contain keratohyalin granules, which are filled with proteins that promote hydration and cross-
linking of keratin. The cornified layer is a layer of dead and hardened remnants of the keratinocytes
after losing most of their nuclei. The dermis is the lower layer of the skin. It is a layer of connective
tissue consisting of a mixture of collagen fibers and elastic fibers, embedded in proteoglycans. It
contains hair follicles, vessels (blood and lymphatic) and glands (sweat and sebaceous). Small numbers
of antigen presenting cells (dendritic cells or macrophages) and lymphocytes (T or B cells) is present in
the epidermis and the dermis adapted from (Crow, 2012).
Psoriasis is a systemic chronic immunological disease characterized primarily by
abnormal accelerated proliferation of the keratinocytes in the epidermal layer of the skin.
Although the main feature of the psoriasis is the pathognomonic silver, scaly, raised and
inflamed skin patches, the disease is connected to a number of complications related to
other organs such as the joints, heart, liver and lungs.
In the United States the incidence of psoriasis is 200,000 cases each year. The
majority of these cases present before the age of thirty five (Enamandram and Kimball,
2013). In European children the prevalence of psoriasis is 0.71% (Augustin et al., 2010a)
while its almost absent in Asian children (Chen et al., 2008).
In relation to the age group prevalence, there are two age peaks, the first around
twenty five and the other around thirty five in many European countries (Falk and
Vandbakk, 1993; Ferrandiz et al., 2001; Simpson et al., 2002). Studies from the United
Kingdom, Germany, Russia, and United States showed an additional prevalence peak
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around the age of sixty (Gelfand et al., 2005; Javitz et al., 2002; Schmitt and Ford, 2010;
Seminara et al., 2011; Stern et al., 2004).
Regarding the gender there is a discrepancy in studies done in different countries.
While in Germany (Augustin et al., 2010b), UK (Gelfand et al., 2005) and Norway (Falk
and Vandbakk, 1993) there is a slight increase in the incidence in females than males, the
opposite is reported in Denmark (Brandrup and Green, 1981) and Australia (Plunkett et al.,
1999).
The Psoriasis Disability Index (PDI) is a clinical tool to assess the impact of
psoriasis on patients’ quality of life. From this it was obvious that psoriasis decreases the
quality of life and that this impact is directly proportional to the extent of skin involvement
(Gelfand et al., 2004). The more severe the disease is and the more the joints are involved
(PsA: Psoriatic Arthritis); the more the direct (e.g. Hospitalization) and indirect medical
costs (e.g. Lost productivity) per patient are. In a study of PsA patients in the UK, annual
costs per patient ranged from £548 to £4,832 according to the severity of the disease (Poole
et al., 2010).
1.4.2. Presentation of Psoriasis
One of the most commonly used grading systems in clinics is the Psoriasis Area and
Severity Index (PASI). To classify psoriasis patients, it uses the severity of the lesions in
combination to the area affected (Langley and Ellis, 2004). In clinical management it is
important to classify the psoriasis according to the different clinical varieties it presents
with. Psoriasis present in patients in many degrees and forms. Even in a single patient the
severity of the psoriasis vary during the course of the disease. The presentation could
include itchiness and/or pain, or maybe totally devoid of them. In clinical practice 80% of
cases are mild (PASI index) plaque psoriasis. In plaque psoriasis the patches are distributed
symmetrically and commonly seen on the scalp. Other less common forms of psoriasis
include guttate psoriasis, inverse/flexural psoriasis, pustular psoriasis and
erythrodermic/exfoliative psoriasis  (see figure 7) (Crow, 2012).
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Figure 1.9: Clinical patterns of Psoriasis.
In this figure the red color on the human figures illustrate the distribution of each of the main clinical patterns
of psoriasis. The photograph under each human figure shows an example of the NE of each of the listed
clinical patterns. Modified from (Crow, 2012).
The connection between the development of psoriasis and other system affection is
an idea that is becoming popular, as evidence on psoriasis related non skin diseases are
increasing. PsA has become a separate type of arthritis with direct connection to the
pathology of psoriasis. The prevalence of PsA in psoriatic patients is 18% in average (Lloyd
et al., 2012). The clinical symptoms of PsA vary and are not always correlated with the
severity of psoriasis of the skin (Gottlieb et al., 2008). In most of cases, PsA appears in
psoriasis patients about ten years after the skin manifestations (Prey et al., 2010).
Table 1: Method for calculating the Psoriasis Area and Severity Index (PASI). Shown is the original
description of the PASI which involves the assessment over 4 body regions (head [h], trunk [t], upper
[u] and lower [l] extremities) of erythema (E), infiltration (I), and desquamation (D), and body
surface area involvement (A). Because the head, upper extremities, trunk, and lower extremities
correspond to approximately 10%, 20%, 30%, and 40% of body surface area, respectively, the PASI
score is calculated by the formula:
PASI = 0.1(Eh + Ih + Dh)Ah + 0.2(Eu + Iu + Du)Au + 0.3(Et + It + Dt)At + 0.4(El + Il + Dl)Al.
(Langley and Ellis, 2004)
(a) (b)
Degree of Severity
(per body region) Value given
Surface involved
(per body region)
Value
given
No symptoms 0 <10% 1
Slight 1 10%-29% 2
Moderate 2 30%-49% 3
Marked 3 50%-69% 4
Very marked 4 70%-89% 5
90%-100% 6
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1.4.3. Co-morbidities of Psoriasis
The epidemiological risk factors of Psoriasis are shared with the risk factors of
cardiovascular diseases (Kimball et al., 2012). Several studies point to an increasing
statistical correlation between moderate to severe psoriasis and the development of
cardiovascular conditions (Ahlehoff et al., 2011). The association between psoriasis and
cancer arises from the side effects of immunosuppressive drugs used for its treatment (Shu
et al., 2011). There is a proven positive correlation between psoriasis and depression
(Dowlatshahi et al., 2013). Cytokines that are involved in the pathogenesis of psoriasis are
also connected with depression (Kurd et al., 2010). Other co-morbidities associated with
psoriasis include type 2 diabetes, hypertension and obesity (Naldi and Mercuri, 2010).
1.4.4. Molecular Aspects of Psoriasis
Psoriasis was found to be linked to 36 genomic regions (psoriasis susceptibility loci,
PSORS) through several genome-wide association studies (GWAS). The most important
genes identified within these regions are genes on the chromosome 17q25 (PSORS2):
SLC9A3R (solute carrier family 9, isoform 3 regulatory factor), NAT9 (N-acetyltransferase
superfamily), and RAPTOR (rapamycin (TOR); and CARD15 on the chromosome 16q
(PSORS8) (Filer et al., 2009; Samuelsson et al., 1999). SLC9A3R and NAT9 susceptibility
to psoriasis is related to mutations of the RUNX1 binding site within these genes (Helms et
al., 2003). RUNX1 is a gene involved in the development of haemopiotic cells. Also,
mutations in the SLC9A3R include ones that lead to functional changes in the immune
synapse that is believed to increase in the stimulatory effect on the T lymphocytes giving
more chronicity to the inflammation (Itoh et al., 2002). CARD15 is a component of the
activation cascade leading to of NF-кB activation and is involved in the innate immune
response (Li et al., 2012). Other   GWAS draw attention to other members of the NF-кB
signaling pathway involved in psoriasis: TNFAIP3 (TNF-inducible protein 3), TNIP1
(TNF-inducible protein 1), NFKBIA (NF-кB inhibitoty protein α), and TRAF3IP2 (TRAF3
interacting protein 2) (Nair et al., 2009; Strange et al., 2010).
The skin is not a mere physical barrier against harmful environment, rather an active
component of the immune system. In healthy individuals the injury of the skin leads usually
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to a limited inflammation and regeneration of the epidermal layer. On the other hand, in a
genetically predisposed individual, the precipitating event (Trauma, Infection, Drugs, UV
…etc.) leads to keratinocytes activation followed by immune cell activation. Further on, the
immune activation in these patients leads to a loop of exaggerated regeneration and chronic
inflammation characteristic to psoriasis. Because of the evident role of the T cells in the
pathogenesis, the early trials to investigate psoriasis declared the adaptive immunity as the
main perpetrator in psoriasis. More recent studies, including GWAS, presented evidence
that innate immunity is another accomplice in the process of psoriasis development (Tsoi et
al., 2012). Also, there is recent evidence that in psoriasis the tolerance towards self antigens
is defective. The immune cells react towards RNA and DNA released from the
keratinocytes in the process of inflammation (Lande et al., 2007). The up to date cellular
picture of psoriasis include keratinocytes (KCs), dendritic cells (DCs), T cells , B cells,
natural killer cells (NKs), macrophages and mast cells .
Figure 1.10: Immunological events in psoriasis.
The figure illustrates a scheme of the epidermis with the different layers of keratinocytes. The skin on the left
side represents the normal skin. The skin on the right represents skin in a psoriasis patient. Different cells and
molecules that share in the pathogenesis of psoriasis. Th: T hepler cell, iDC: immature dendritic cell, mDC:
mature dendritic cell.
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The skin injury drives stress and activation in KCs which produce cytokines (eg. IL-
1, IL-6, IL-18 and TNF-α) and antimicrobial peptides (AMPs: eg. S100A and C-type
lectins). AMPs act as opsonins attracting macrophages and neutrophils to the site of
inflammation. The cytokines lead to further KC maturation and activation of DCs (Johnston
et al., 2011). Important DCs that are involved in the psoriatic reaction are the plasmacytoid
DCs (pDCs) that are involved in antiviral response through endosomal Toll-like receptor 7
(TLR-7) and TLR-9. The mDCs activate different subsets of T cells, most importantly Th1,
Th17 and Th22 (Skrzeczynska-Moncznik et al., 2012). These cells close the viscous loop of
the psoriasis reaction in psoriasis patients through releasing TNF , IL-17 and IL-22
respectively; and affecting the KCs and other cells in the skin (Blumberg et al., 2007;
Chung et al., 2009; Guilloteau et al., 2010).
1.4.5. Treatment of Psoriasis
The treatment options of psoriasis include local (topical), systemic and
phototherapy. They are used as a monotherpay, combination therapy, rotation therapy or
sequential therapy according to the patient and the presentation of the disease. Topical
agents include: tar, anthralin, retinoic acid, Vitamin D, corticosteroids and topical
immunomodulators. Systemic treatment include: cyclosporin, methotrexate, retinoids and
targeted immunotherapy. Phototherapy can be done using ultraviolet rays (UV) or excimer
laser; which is also a form of ultraviolet laser. UV maybe broad band, narrow band or
PUVA (psoralen with ultraviolet A rays) (Papoutsaki and Costanzo, 2013).
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2. Aim of the Work
2.1.1. The Role of NFATc1 in Normal lymphocyte physiology and pathological
conditions.
2.1.1.1. Investigate whether NFATc1/αA acts as an oncogene for the development of
lymphoid tumors.
2.1.1.2. Investigate molecular mechanisms through which constitutive NFATc1/αA
may alter the program of normal lymphocyte development?
2.1.1.3. Investigate the role of NFATc1 in Autoimmunity (IMQ-Induced Psoriasis
Model in Mice)
2.1.2. Elucidate the points of interactions between the NFAT and the NF-kB pathways in
activated B-cell fate.
2.1.3. IRF4 role in lymphocytic transformation.
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3. Material and Methods
3.1.Materials
3.1.1. Antibodies
3.1.1.1. Primary antibodies for FACS analysis (anti-mouse)
AnnexinV APC BD Pharmingen
B220 Biotin BD Pharmingen
B220 FITC eBioscience
B220 PE eBioscience
AA4.1 Biotin BD Pharmingen
CD3 PE eBioscience
CD19 PE eBioscience
CD19 FITC BD Pharmingen
CD16/CD32 (Fc-Block) - eBioscience
CD138 FITC BD Pharmingen
CD23 FITC BD Pharmingen
CD1d PE BD Pharmingen
CD21 PE BD Pharmingen
CD43 FITC eBioscience
CD4 FITC BD Pharmingen
CD5 PerCP-Cy5.5 eBioscience
CD5 PE eBioscience
CD8a APC-eFlour 780 eBioscience
IgM APC BD Pharmingen
IgM FITC eBioscience
IgD PE eBioscience
Streptavidin APC eBioscience
Streptavidin eFluor 450 eBioscience
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3.1.1.2. Primary antibodies for Western Blot and immunofluorescence analysis (anti-
mouse)
Mouse anti-NFATc1 (clone 7A6) BD Pharmingen
Rabbit anti-NFATc1α (polyclonal) Immunoglobe
Rabbit anti-NFATc2 (polyclonal) CellSignaling
Rabbit anti-NF-κB p65 (D14E12) CellSignaling
Rabbit anti- NF-κB p52 (polyclonal) Abcam
Rat anti-F4/80 Biotin (clone CI:A3-1) BioLegend
3.1.1.3. HRP-coupled secondary antibodies for Western Blot analysis
Goat anti-mouse HRP Sigma-Aldrich
Goat anti-rabbit HRP Sigma-Aldrich
3.1.1.4. Fluorescent-coupled secondary antibodies and reagents for
immunofluorescence
Donkey anti-mouse Alexa 555 Molecular Probes
Donkey anti-rabbit Alexa 488 Molecular Probes
Donkey anti-rat Alexa 488 Elita Avota, Uni. Wü
3.1.2. Antibiotics and inhibitors
FK506 (Tacrolimus) Calbiochem
GolgiStop (Monensin) Sigma-Aldrich
HALT protease inhibitor cocktail BD Bioscience
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3.1.3. Chemicals
Acetic acid Roth
Agar Roth
Agarose Roth
β-Mercaptoethanol Roth
Bradford reagent BioRad
Bromophenol blue Sigma-Aldrich
[α-P32]-dCTP Hartmann Analytic
Disodium hydrogen phosphate (Na2HPO4) Roth
Dimethyl-sulfoxide (DMSO) Roth, Gibco
Dulbecco's Modified Eagle Medium Gibco
6x DNA loading Dye Fermentas
EDTA Roth
Ethanol (EtOH) Roth
Ethidium Bromide (EtBr) Roth
Fetal Bovine Serum, Qualified, US origin Gibco
Fluoroshield with DAPI Sigma-Aldrich
Glycine Roth
Glycerol Roth
Hydrogen chloride (HCL) Roth
Isopropanol Roth
LB medium Roth
Magnesium chloride Roth
Magnesium chloride (MgCl2 25mM) PeqLab
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Methanol Roth
Midori Green Nippon Genetics
Monosodium phosphate (NaH2PO4) Roth
Non-fat dried milk powder AppliChem
2xPCR Mix Fermentas
Phenol Roth
Penicillin (10000U)/Streptomycin (10000µg) Gibco
Ponceou S Sigma-Aldrich
Power SYBR Green Sigma-Aldrich
PCR Master Mix AB
Propidium iodide Sigma-Aldrich
protein G agarose Pierce
Rotiphorese®Gel 30 Roth
Sodium citrate Roth
Sodium chloride (NaCl) Roth
Sodium dodecyl sulfate (SDS) Roth
Sodium hydroxide (NaOH) Roth
Triton-X-100 AppliChem
Tris Roth
Trypan Blue Solution Sigma-Aldrich
Trypsin/EDTA Gibco
dH2O was taken from the “Biocel MilliQ system” (Millipore), if not differently
indicated.
Materials and Methods 25
3.1.4. Electronic data processing
Data were collected, analyzed and presented using several Microsoft
Windows operated computers (Toshiba laptop and Fujitsu-Siemens desktop) and a
scanner from HP. Following programs were used:
FlowJo (Version 7.6.2)
BD FACS Diva 5.0
FUSION CAPT
GraphPad Prism 6
Thomson EndNote X3
Image Lab Software
Adobe Photoshop CS6
Adobe Illustrator CS6
Leica Software ImagePro Plus
Microsoft Office Excel 2007
Microsoft Office PowerPoint 2007
Microsoft Office Word 2007
3.1.5. Equipment
Cell culture plates (96 well)                                Greiner, Nunc
Cell culture plates (48, 24, 12, 6 well)                Greiner, Nunc
Cell culture plates (6cm, 10cm)                          Greiner, Nunc
Cell culture flasks (75cm2 flask) Greiner
Cell separation columns (LS) M. Biotech
Cell scraper (24mm)                                            Hartenstein
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Cell strainer (70µm)                                            BD Bioscience
Cover slips Marienfeld
Cryo tube (2ml)                                                   Greiner
Cuvette (quartz) Hellma
Cuvette (plastic)                                                  Braun
Erlenmeyer flasks (1000ml, 500ml, 100ml) Schot
FACS tubes                                                         BD Bioscience
50ml & 15ml falcon tubes Greiner
Forceps for animal preparation                           Hartenstein
Hybridization mesh                                             Thermo Fisher
Hybridization bottle                                            Thermo Fisher
Hyperfilm ECL Amersham
Freezing container                                               Nalgene
Microcentrifuge tubes (1.5ml, 2ml)                    Eppendorf
Object slides Hartenstein
Parafilm                                                               Pechiney
Pasteur-pipettes                                                   Hartenstein
PCR plates, white (96 well)                                Thermo Fisher
Pipette tips (1000µl, 100µl, 10µl)                       Sarstedt
Razor blades                                                        Hartenstein
Scissor for animal preparation                            Hartenstein
Serological pipette (25ml, 10ml, 5ml, 2ml)        Greiner
Sterile filters (0.2µm, 0.45µm)                           Sartorius
Syringe (2ml, 5ml, 10ml)                                    Braun Syringe
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Needle (23GA, 20GA) Hartenstein
Tuberculin syringe (26 GA 3/8")                        Braun
Protran BA 85 Nitrocellulose                              GE Healthcare
Wathman 3MM filter paper                                Hartenstein
X-ray cassette                                                      Hartenstein
3.1.6. Instruments
Autoclave                                                            Systec
Balance FCB                                                       Kern
Biofuge 15R                                                        Heraeus
Confocal microscope TCS SP5 II                       Leica
Gel DocTM XR+ BioRad
Electrophoresis chamber                                     CTI
Electrophoresis Power Supply                            Micro-Bio-Tec
FACS Canto II BD
Fridge (4-10°C, -20°C, -70°C)                            Siemens
Fusion SL                                                            V. Lourmat
Ice machine Genheimer
In vivo imaging system (Maestro EX)                CRI
Light microscope CK2                                        Olympus
LUMIstar Omega                                                BMG labtech
Centrifuge 5418 Eppendorf
Humidified tissue culture incubators                  Heraeus
instruments Hybridization oven Bachofer
Thermomixer compact                                        Eppendorf
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7000 Sequence Detection System Applied BioS.
Shaker C40                                                          GLW
Waterbath                                                            Hartenstein
T100 Thermocycler BioRad
Tank Blot                                                             Hoefer
PCR machine Biometra
Photometer                                                          Pharmacia
pH-meter WTW
Vertical electrophoresis unit                               Hoefer
Vortex mixer                                                       RA
3.1.7. Ligands and stimulants
Anti-IgM μ-chain F(ab)2 Jackson ImmunoResearch
Ionomycin Sigma-Aldrich
LPS, ultra-pure                       Sigma-Aldrich
TPA (PMA)                             Merck
3.1.8. Kits
B cell Isolation Kit, mouse Miltenyi Biotech
CellTrace™ Kit Molecular Probes
DecaLabel™ DNA Labeling Kit                         Fermentas
First Strand cDNA Synthesis Kit                        Fermentas
Intracellular Fixation & Permeabilization eBiosciene
Long PCR Enzyme Mix                                      Fermentas
NucleoBond Xtra Maxi Mach.-Nagel
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2x PCR Mix                                                         Fermentas
SuperSignal West Pico ECL Substrate               Pierce
3.1.9. Mice
All mice were kept in a species appropriate environment at 22°C with a 12 hours
circadian rhythm in the animal facilities of the Institute of Pathology, the Institute
of Microbiology & Hygiene and at the Center of Experimental Molecular Medicine
(ZEMM) of the University of Würzburg.
All offspring were genotyped around the fourth week after birth. The used
experimental animals were 8-18 weeks old gender-matched littermates. For some
experiments age- and gender-matched wild type mice were used as control. All used
mouse lines were maintained on C57BL/6 background.
3.1.10. Reverse Transcriptase (RT) and Real-Time PCR Primer
P2 (Ex2/3-Ex3) fwd aggacccggagttcgacttc
P2 (Ex2/3-Ex3) rev gcagggtcgaggtgacactag
P1 promoter fwd gggagcggagaaactttgc
P1 promoter rev cagggtcgaggtgacactagg
qRT NFATc1 fwd gatccgaagctcgtatggac
qRT NFATc1 rev agtctctttccccgacatca
Actin fwd gacggccaggtcatcactattg
Actin rev aggaaggctggaaaagagcc
2.1.14 Size standards
DNA ladder (Fermentas): GeneRuler 100 bp
Protein ladder (Fermentas): PageRuler prestained
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3.2.Methods
3.2.1. Generation and maintenance of genetically modified mice
3.2.1.1. Irf4 flx/flx x mb1-cre mice
mb1-cre transgenic mice were created in M. Reth's laboratory by inserting hCre into
the mb-1 WT locus between the exons 2 and 3 (Hobeika et al., 2006). They allow the
inactivation of “floxed” genes in bone marrow B cells. Irf4 floxed mice were created in
the Dalla-Favera laboratory by flanking  the chromosomal murine Irf4 gene with loxP
sites which are targets of Cre recombinase of bacteriophage P1. These two lines were
crossed to produce the Irf4 flx/flx x mb1-cre mice line that have the Irf4 gene floxed and
express mb1-cre. Therefore, having B-cells lacking IRF4 expression start as early as the
bone marrow.
3.2.1.2. caNFATc1/αA x Irf4 flx/flx x mb1-cre mice.
In the laboratory of Prof. Volker Ellenrieder (Department of Gastroenterology, Univ.
Marburg) a transgenic mouse line was created expressing a constitutive active version of
the NFATc1/αA isoform under the control of a “floxed” Stop cassette from the ROSA26
(R26) locus (which is an “open” locus that is broadly used for expressing transgenes in
mice). These mice we refer to by, caNFATc1/αA. When this cassette is deleted by Cre,
the caNFATc1/αA version is expressed. By crossing this line with the Irf4 flx/flx x mb1-
cre line, we got mice having B-cells that (over-) express NFATc1/αA (from the
ROSA26 locus) and lack IRF4 expression starting as early as the bone marrow.
3.2.1.3. caNFATc1/αA X NFATc1 flx/flx X cd23-cre mice.
Cd23-cre transgenic mice were created in M. Busslinger`s laboratory by inserting a
Cre-IRES-hCd5t expression cassette into exon 2 of a Cd23 BAC construct (Kwon et al.,
2008). Those mice were crossed with the Nfatc1 flx/flx mice in which the Nfatc1 gene is
flanked with loxP sites then crossed with the caNFATc1/αA mice to give a line in which
splenic B-cells do not have any NFATc1 expression except the (over-)expression of
NFATc1/αA from the ROSA26 locus.
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3.2.1.4. c-RelKo mice.
c-Rel knockout mice where originally created by the Kontagen group (Kontgen
et al., 1995) and used in our experiments.
3.2.2. Genotyping of mice
Genotyping was done with 4 weeks old mice. The tip of the tail was cut using a
scalpel and put in an eppendrof tube. 30 µl of proteinase K (Fermentas; #EO0491) were
added per 1 ml genomic lysis buffer and 20 µl of the cocktail were added to each tail
sample following overnight incubation at 56°C. The next day 480 µl of water was added
to each sample and incubated for another 10 min at 95°C. Following centrifugation, 3 µl of
DNA sample was used to run PCR assays using the following primer pairs:
Detection of caNFATc1/αA gene
caNFAT for 5'-cat gtc tgg gag atg gaa gc-3'
NFAT rev 5'-tct cga gct act tgt cat cg-3'
Detection of Rosa26 wild type gene
Rosa26 for 5'-ggc gga tca caa gca ata at-3'
Rosa26 rev 5'-gag tct tct ggg cag gct ta-3'
Detection of mb1 wild type gene
Mb1 for 5’-CTGCGGGTAGAAGGGGGT-3’
Mb1 rev 5’-CCTTGCGAGGTCAGGGAGCC-3’
Detection of cre gene
iCre for 5’-ACCTCTGATGAAGTCAGGAAGAAC-3’
iCre rev 5’-GGAGATGTCCTTCACTCTGATTCT-3’
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Detection of the NFATc1 floxed gene
NFATc1 flx/flx for 5’-CCTATTTAAACACCTGGCTCCCTGCG-3’
NFATc1 flx/flx rev 5’-CCATCTCTCTGACCAACAGAAGCCAG-3’
Detection of the IRF4 floxed and wild type genes
IRF4 flx/flx for 5’-TGC CTT TGG GAC GGA TGC TC-3’
IRF4 flx/flx wt rev 5’-CTT CTA GCT GAC CAC TAA GAA C-3’
IRF4 flx/flx flx rev 5’-GAC CAC TAC CAG CAG AAC AC-3’
Detection of the c-Rel knock out and wild type genes
c-Rel WT for 5’-GTA CTG CAT CAA CTG CAT GAC-3’
c-Rel WT rev 5’-CAG AGA CTA ACA AGT GGT A-3’
c-Rel Ko rev 5’-CTT CCT CTT CTC TGC CAG AC-3’
Genomic lysis buffer:
300mM NaCl
25mM EDTA
50mM Tris (pH 8.0)
0.2% SDS
3.2.3. Lymphocyte isolation
Age (8-10 weeks old) and sex matched animals were sacrificed and dissected
followed by the removal of spleen and BM and LNs. BM cells were flushed out using a
syringe and PBS.
To obtain peritoneal cells, glass pipettes and PBS were used. Single cell populations were
obtained from all specimens using a cell strainer (Hartenstein). Erythrocytes were lysed
with TAC buffer. B cell isolation was done using Miltenyi’s B cell isolation kit (#130-
090-862) according to manufacturer’s instructions with a yield of 95-98% pure B cell
population.
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TAC buffer
8.26 g NHCl
1 g KHCO
0.037 g EDTA
Dissolved in 1000 ml ddH2O; Mix well and autoclave
3.2.4. Cell counting
To determine cell numbers cells were diluted with Trypan Blue to exclude dead
cells and filled under a cover slid on a Neubauer counting chamber. Four fields were
counted (≥ 10 cells) and the cell number was calculated according the mean of four
and the dilution factor of the chamber (1x104) per ml
3.2.5. Cell culture
5x106 cells were cultured in 1 ml X-vivo 15 medium (BE04-418Q; Lonza). Incubations
were done for periods ranging from 15 minutes to 72 hours. Stimulations were done by LPS
(10 µg/ml; Sigma, #L5293), α-IgM (10 µg/ml; Jackson Lab., #115-006-020), α-CD40 (2
µg/ml; R&D, #MAB440) or TPA (Sigma, #79346) and ionomycin (Invitrogen, #I24222) or
combinations of them. For harvesting, the cells were sucked from the wells and then washed
twice with cold PBS.
PBS
8 g NaCl
0.2 g KCl
1.44 g Na2HPO4
0.24 g KH2PO4
Dissolved in 800 ml ddH2O; adjust pH to 7.4 with HCl, add ddH2O to 1 Liter.
3.2.6. Protein extraction
3.2.6.1. Whole cell protein extraction
Whole protein extract was prepared by incubation of cells on ice with modified
RIPA buffer for 15 minutes followed by hard vortexing at 4°C for 30 minutes followed
by centrifugation and sucking the supernatent.
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Modified RIPA buffer
150 mM NaCl
1.0% NP-40 (Sigma)
0.5% sodium deoxycholate
0.1% SDS
50 mM Tris, pH 8.0
3.2.6.2. Nuclear and/or cytoplasmic protein extraction
All steps are done in the cold room. The amounts are adjusted to 5-10 X 106 cells.
The cells are washed twice with 1 ml ice cold PBS (2000 rpm for 3 minutes.). After
the second wash 120 µl of ice cold buffer A is added and let sit on ice for 15 minutes.
Then, 25 ul 10% NP-40 is added and vortexed for 30 seconds then let sit 30 seconds.
The nuclei are pelleted by centrifugation at 9000 rpm for 60 seconds. After that, the
supernatant (cytoplasmic proteins) was carefully remove from the pellet and
discarded or put in pre-chilled microcentrifuge tubes. 52 μl of ice cold buffer B is
added to resuspend the nuclear pellet followed by vigorous agitation (vortex) for 30
minutes. Nuclear extracts (supernatants) are recovered after centrifugation for 15
minutes at 12000 rpm and put in pre-chilled microcentrifuge tubes. Both cytoplasmic
and nuclear proteins contained in the buffers were stored at -70º.
Buffer A (Hypotonic):
10 mM HEPES pH 7.9
10 mM Kcl
0.1 mM EDTA
0.1 mM EGTA
Buffer B (High salt):
20 mM HEPES pH 7.9
0.4 M NaCl
1 mM EDTA
1 mM EGTA
20% Glycerol
For each buffer just before extraction add:
2 mM DTT
0.5 mM PMSF
10μl/ml Halt Protease Inhibitor Cocktail (Pierce biotechnology)
Materials and Methods 35
3.2.6.3. Bradford assay
The Bradford assay kit from BIORAD was used to estimate the protein
concentration according to manufacturer's protocol. This assay is based on complexes
built between the Bradford reagent (Coomassie-Brilliant-Blue G-250) and proteins
under acidic conditions, leading to different absorption characteristics at 595 nm wave
length. The standard curve was prepared with BSA solution at serial concentrations
covering the estimated sample concentration range.
3.2.7. Expression analysis
3.2.7.1. Western blot
Equal amounts of protein were loaded for each sample per lane (minimum of
30 µg) for the separation on SDS-PAGE gels. Nitrocellulose membranes
(WHATMAN, #BA 85) were used for protein transfer. Membranes were blocked
using 4% non-fat dry milk in TBS-Tween buffer for 1 hour on shaker. The membranes
were incubated with primary antibodies in TBS-Tween buffer over night at 4°C on a
shaker. Then secondary antibodies (α-mouse or α-rabbit) were used in TBS-Tween
buffer according to the source of primary antibodies for 1 hour on a shaker. Signals
were developed using Super SignalTM kit (Pierce Chemical Company, CA) and
imaged using Fusion-SL system (Vilber Lourmat) or with an X-ray film (Hyperfilm
ECL, Amersham). To confirm equal loading, the membranes were re-blotted with β-
actin (AC-15mAb; Sigma, #A1978).
10% Resolving gel (10 ml)
H2O 4.0 ml
30% Polyacrylamide (Applichem) 3.3 ml
1.5 M Tris (pH 8.8) 2.5 ml
10% Ammonium persulfate (APS) (Sigma) 0.1 ml
10% Sodiumdodecyl sulfate (SDS) (Roth) 0.1 ml
TEMED (Sigma) 0.004 ml
Stacking gel (3 ml)
H2O 2.1ml
30% Polyacrylamide (Applichem) 0.5 ml
1.5 M Tris (pH 6.8) 0.25 ml
10% Ammonium persulfate (APS) (Sigma) 0.3 ml
10% Sodiumdodecyl sulfate (SDS) (Roth) 0.3 ml
TEMED (Sigma) 0.003 ml
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Running buffer (TG Buffer)
3.02 g Tris
18.8 g Glycine (Roth)
10 ml 10% SDS
ddH2O added to 1 Liter
Transfer buffer
72.5 g Glycine
14.5 g Tris
1 liter methanol
ddH2O added to 5 Liter
Wash buffer (TBS Tween)
2.42 g Tris
8 g NaCl
ddH2O added to 1 Liter and add 450µl of Tween.
3.2.7.2. RT-PCR
Cells were suspended in 1 mL Trizol and stored at -70°C. Prior to RNA
extraction, the tubes were allowed to thaw at room temperature and 200 µl of
chloroform (Roth) was added to the samples. After 5 minutes incubation at room
temperature, the tubes were vortexed for 10 seconds and then centrifuged at 4°C and
12000 rpm for 10 minutes. Then, the aqueous upper phase was transferred into a new
autoclaved (RNase free) microcentrifuge tube and 500 µL of isopropanol (Roth) were
added. After a short vortex, the cells were incubated at room temperature for 10
minutes and centrifuged at the 12000 rpm for 30 minutes.  The supernatant was
discarded and the pellet was washed with 1 ml of 75% Ethanol (Roth), then air-dried
before re-dissolving in 10 µL of DEPC water (Roth). The newly extracted RNA was
mixed with 1 µl of 6x loading dye and run on a 1% agarose gel to check for
degradation.
1 µg of total RNA was used to synthesize cDNA using the iScript™ cDNA
Synthesis Kit (BIO-RAD).  cDNA preparation was done using Titan One Tube RT-
PCR System (Roche Diagnostics). 2XPCR Master Mix (Thermo Scientific) and Gene
Ruler™ 100bp (Thermo Scientific) ladder were used.
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1% Agarose gel
1 g Agarose (Applichem)
100 ml   TAE Buffer (1x)
10 µl Ethidium bromide (Roth)
50x TAE buffer
242 g Tris base
57.1 ml Acetic Acid
100 ml 0.5 M EDTA
ddH2O added to 1 Liter
6x DNA loading dye
3 ml glycerol (30%)
25 mg bromophenol blue (Roth)
ddH2O added to 10 ml
3.2.7.3. Electrophoretic mobility shift assay (EMSA)
EMSA is an electrophoresis technique used to study protein–nucleic acid
interactions. Using a radioactive labeled oligonucleotide probe mixed with the protein
extracts of cells the binding is determined by the higher position shifting  of the complex
(or part of the complex) when running on polyacrylamide gel in comparison to the free
running probes. The higher position is due to the slower mobility through the gel due to
the larger size of protein + nucleic acid complex. The specificity of this binding is
determined by either competition by an excess of a known factor binding probe or by
adding an antibody specific for a transcription factor to the mix producing a supershift.
The position of the complexes and the upper shifting are detected by the radioactive
impression of the complex on an X-ray film (Hyperfilm ECL, Amersham).
We prepared radioactive labeled double-stranded probe that were approximately 25
bp in length corresponding to NFATc1 and NF-кB binding sites. After extraction of
nuclear proteins from cells, the protein concentration of extracts was measured. Equal
amounts of nuclear proteins were incubated with a mixture of the radioactively labeled
double-stranded probe, 3xBi-Buffer and Poly(deoxyinosinic-deoxycytidylic) acid
sodium salt (Poly dI-dC) at -4〬C for 30 minutes. The mixture was loaded on a 6% non-
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denaturing polyacrylamide gel and fractionated for about 3 hours using 0.5X TAE as
running buffer. After the run, the gel was fixed using 10% acetic acid, dried on a
vacuum gel dryer for 1 hour, then exposed to an X-ray film in a well sealed X-ray
cassette overnight at -70° C. Longer exposure periods up to 72 hours were often needed.
3x Binding buffer
HEPES 7.9 pH 60 mM
DTT 3 mM
EDTA 3 mM
KCL 150 mM
Ficoll 12 %
50X TAE Stock Solution
For each litre of solution:
242 g Tris Base
57.1 ml Glacial Acetic Acid
100 ml 0.5 M EDTA
Mix Tris with stir bar to dissolve in about 600 ml of ddH2O, then add the EDTA
and acetic acid. Finally, bring final volume to 1 l with ddH2O and store at room
temperature.
3.2.8. Cell staining and sorting
3.2.8.1. Flow-assisted cytometric analysis (FACS)
The principle of FACS is based on the passage of cells in a single cell flow across a
beam of laser. According to the interaction of the laser with the cells (native) or
fluorescence-labeled antibodies they carry, the cells are measured and analyzed.
Information gathered from these events include their numbers (events), their size
(forward), granularity (side scatter) and fluorescent properties. Cells could be analyzed
for structure and expression of surface molecules and intracellular proteins. We used the
FACS Canto II (BD).
3.2.8.2. Surface marker staining
To stain cells with fluorescent labeled antibodies 0.5-1x106 cells were
transferred into 1.5 ml reaction tubes and washed twice with FACS-Buffer
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(PBS/0.1%BSA) and suspended in a total volume of 50 µl FACS-Buffer. A master mix
of the fluorescent antibodies (0.25 µl antibody/sample) and the Fc-Block (1:250)  was
prepared in 50 µl  FACS-Buffer per sample. 50 µl of the master mix was added to each
sample tube. Samples were incubated with antibodies for 15 minutes at room
temperature in the dark. After two more washing steps the cells were directly measured,
continued for intracellular marker staining or fixed in 4% formaldehyde.
3.2.8.3. Intracellular marker staining
Cells were stimulated in culture with different stimuli for different time periods.
TPA (Sigma), ionomycin (Invitrogen) and Golgi-plug (BD) were added to the
culture for the final 6 hours. The cells were harvested, washed then stained for the
surface markers according to the previous protocol. After that, cells were fixed and
permeabilized using eBioscience fixing and permeablizing kit according to
manufacturers recommendations, then stained with anti-mouse IL-10 APC antibody
(eBioscience). Prior to FACS measurement, they were re-washed and re-suspended
in FACS buffer.
3.2.8.4. Proliferation assay
Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) is colorless and
nonfluorescent until the acetate groups are cleaved by intracellular esterases to yield
highly fluorescent carboxyfluorescein succinimidyl ester (CFSE). The succinimidyl
ester group reacts with intracellular amines, forming fluorescent conjugates that are
well stable for long times (up to 8 weeks). Due to the acetate groups CFDA-SE
diffuses freely into cells equally and are retained there, passing only through cell
divisions. Due to the progressive halving of CFSE fluorescence within daughter cells
following each cell division, FACS could be used to measure this decrease in the
concentration of the dye in cell populations indicating the frequency and efficiency of
cell proliferation. Purified cells were incubated with CFDA-SE (Invitrogen, #C34554)
at 37〬C for 3 minutes. The cells were then washed with RPMI 1640 (Invitrogen), re-
suspended in X-vivo medium (BioWhittaker) and cultured in a 96-well plate with
various stimuli. At various time points the cells were harvested, washed then
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suspended in 200 µL FACS-Buffer. The approximate excitation and emission peaks of
CFSE are 492 nm and 517 nm, respectively.
3.2.8.5. Apoptosis assay
To investigate apoptosis in our cells we used annexin-V and propidium iodide (PI).
Annexin-V is a protein, which binds to phosphatidylserine on the cell surface of
apoptotic cells. PI is membrane impermeable and therefore intercalates only into the
DNA of dead cells. Two stock aliquots of 100µl/sample of Annexin-binding buffer
(ABB) were prepared in 2 microcentrifuge tubes. To either one of them annexin-V
(APC or FITC) was added with a 1/100 concentration. To the other PI [1mg/ml] was
added in the same concentration. Cells were washed twice using FACS-Buffer, then
100 µl of the annexin-V stock aliquot was added to each sample tube and incubated
for 15 minutes at room temperature in the dark. Just before measuring the samples on
the FACS device 100 µl of the PI stock aliquot was added individually to the sample
tubes. The sample was measured on the FACS within one hour of the beginning of the
staining and each sample was vortexed well before measurment.
Annexin-Binding Buffer:
10 mM               HEPES
149 mM NaCl2
2.5 mM              CaCl2
3.2.9. Psoriasis Induction in mice
After anesthesia of the mouse using intraperitoneal (IP) injection of anesthetic
cocktail Ketamine/Xylazine (50-100 mg/kg of Ketamine-HCl and 5-10mg/kg Xylazine-
HCl), shave 2 x 3 Centimeters of upper back hair carefully. 4.166mg of IMQ cream (Aldara
5%, 3M Pharmaceuticals) is applied to the shaved back of the each mouse daily for a period
of 6-8 days.
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3.2.10. ELISA
Samples were either serum from mice at specified time points of immunization or
supernatant of media where cells were stimulated and incubated for specific time periods.
NUNC Maxisorb 96-well plates (eBioscience) were used to detect the secretion of mouse
IL-10. Samples were serially diluted using dilution buffer and incubated for 2 hours at
37°C. The plates were coated with coating solution and kept at 4°C overnight. Followed
by 2 hours incubation at 37°C with blocking solution and 3 times washing with wash
buffer, samples were added to the plates. Secondary antibodies were then added to the
plates and left overnight at 4°C. Next day, substrate was added to each plate and allowed
to develop color.  The plates were read using a plate reader (Molecular Devices) and
quantifications were done against a standard curve.
Coating solution Anti-mouse IL-10 antibody (Biolegend) in PBS(8 µg/ml)
Blocking solution 1% BSA (Sigma) in PBS + 0.05% sodium azide (Sigma)
Dilution buffer 0.1% BSA in PBS + 0.05% sodium azide
Wash buffer PBS+0.05% Tween 20
Substrate p-Nitrophenylphosphate (Sigma)/1 ml diethanolamine buffer
Diethanolamine buffer (pH 9.8)
0.1 g MgCl2
0.2 g NaAzide
97 ml Diethanolamine ddH2O added to 1 liter
3.2.11. Tissue staining and microscopy
3.2.11.1. Haematoxylin and eosin staining (H & E)
Stain the slides with haematoxylin for 4 minutes, followed by washing under
running tap water for 15 minutes. After that differentiate with 0.3% acid alcohol,
followed by washing under running tap water for 15 minutes. Then stain with eosin for
2 minutes, followed by washing under running tap water for 15 minutes. Finally, tissues
were dehydrated by shortly dipping them in ethanol 100%, then left to dry for 60
minutes at 37〬C and then mounted with cover slip.
Materials and Methods 42
0.3% acid alcohol
Commercial grade ethanol 2800 ml
Distilled water 1200 ml
Conc. hydrochloric acid 12 ml
3.2.11.2. Cytospins and Immunocytochemistry
This is a method to investigate protein expression in fixed single cells. The
visualization of the stained cells is done with several types of microscopes according to
the type of staining. The confocal microscope enables visualization of emitted light of
fluorochrome based stains after excitation with laser light.
After harvesting and washing the cells we repeatedly pipeted and vortexed the cells
to remove any clumps and assure single cell suspension 1x cold RPMI. The cells where
fixed on slides using a cytospin centrifuge with a speed of 350 rpm for 3 minutes. Each
sample had a concentration of 70 - 80x103 cells/slide. Slides were dried at RT for 3-4
hours then they were fixed with 4% paraformaldehyde for 20 min (filtered). After 3
washes with PBS- -, cells were permeabilized by 0.1% Trinton-X in PBS- - (phosphate
buffered saline without supplementation with CaCl2 or MgCl2 ) for 5 minutes at RT.
After 3 washes with PBS - -, cells were blocked for 20 minutes using PBS/0.1% BSA.
After a single wash cells were incubated with the primary antibody for 60 minutes at
RT in humid chamber. After 3 washes with PBS- -, cells were blocked for 20 minutes
using PBS/0.1% BSA. After a single wash cells were incubated with the secondary
antibody 60 minutes at RT in the humid chamber. After 3 washes with PBS- -, cells were
mounted with fluorochrome and DAPI (Fluoroshield, Sigma-Aldrich). PBS- - means that
the phosphate buffered saline buffer does not contain calcium or magnesium.
3.2.11.3. Immunohistochemistry
We performed peroxidase based staining and fluorochrome based staining. In
peroxidas based stainings the detection of the investigated antigen is done by antibodies
labeled with peroxidase and the positive colour (brown) could be detected by light
microscopy on a background tissue stained with haematoxilin (blue). Fluorochrome-
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based staining allows multiple antigen differentiation which help in distinguishing co-
expression and cell specific expression of target proteins. Fluorochrome-based staining
is visualized using confocal microscope of emitted light from the fluorochrome after
excitation with laser light.
After de-paraffinisation of the tissues, antigen retrieval protocols were applied to
the tissues according the primary antibody that would be used. Then, the slides were
left to dry at RT for 15 minutes. The internal peroxidase activity of the tissues was
blocked using peroxidase blocking solution (DAKO s2023 RTU.) for 5 minutes. After
3 washes, tissues were blocked using Ab-diluent (DAKO s2022 RTU.) for 20 minutes.
After that, tissues were incubated with the primary antibody (diluted in proper Ab-
diluent) for 60 minutes. After a single wash, tissues were incubated with the
secondary biotinylated antibody (DAKO 5001 RTU.) for 20 minutes. After a single
wash, tissues were incubated with the the streptavidin-HRP-link (DAKO 5001 RTU.)
for 20 minutes. After a single wash, tissues were dipped in haematoxylin for
background staining, followed by running water for 10 minutes to remove any extra
dye. Finally, tissues were dehydrated by shortly dipping them in 100% ethanol, then
left to dry for 60 minutes at 37〬C and mounted with cover slip. All washings were
done by TBS-buffer. All incubations were done at  RT in humid chamber.
TBS:
50 mMTris
150 mM NaCl
Adjust pH with HCl to pH 7.6
3.2.11.4. Confocal microscopy
A confocal microscope detects the emitted light of fluorochrome after excitation
with laser light. Major advantages of confocal scanning microscopy are its higher
resolution by the usage of two pinholes to blind out diffused light and the possibility to
scan through a whole cell. The pictures were taken with a Leica Confocal microscope
(TCS SP5 II) and analyzed with the Leica Software Image Pro Plus.
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3.2.12. Statistical analysis
The statistical analysis was performed using GraphPad (Prism) software, version
6.0. Data were presented as mean and error bars in figures represent ±SEM (standard
error of mean). Unpaired t-test was performed to evaluate the statistical significance
of the data set. A value of p<0.001(***) is considered highly significant, while
p<0.05(*) as well as p<0.005(**) are known to be statistically significant.
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4. Results
4.1. Expression of a constitutive active version of NFATc1 (caNFATc1/αA) with ablated
IRF4 in B cells from mice.
The role of NFATc1 in the development of B cells was investigated in our group
and other groups in several previous studies (Muller and Rao, 2010; Serfling et al., 2012).
We studied this by inactivating the Nfatc1 gene at different levels of B cell development
by using different types of mouse cre-lines. For example, the mb1cre line (starting
expression in BM) and CD23cre line (starting expression in spleen) with the floxed
version of the Nfatc1 gene were used. We showed that the knock out of NFATc1 does not
alter B cell compartment in BM or spleen regarding numbers. However, it impairs the
development of peritoneal B1a cells (Bhattacharyya et al., 2011). In this work we wanted
to further investigate (i) NFATc1 role in B cell development deploying a constitutive
active version of the short NFATc1 isoform NFATc1/αA, designated as caNFATc1/αA,
and (ii) the interplay between NFATc1 and IRF4 in this process. The constitutive active
version of NFATc1 is expressed from the ROSA 26 locus under the control of a STOP
sequence which is ‘floxed’ and, therefore, can be expressed by crossing theses mice with
mouse lines expressing cre. For studying the role of IRF4 we used mice that bear a
‘floxed’ IRF4 allele for its conditional inactivation.
4.1.1. Mice with a constitutive active version of NFATc1/αA show expression of
NFATc1 in splenic B cells without any stimulation.
In order to check the constitutive activity of NFAT in B cells from the
caNFATc1/αA x mb1cre mice we performed a WB with a whole protein from B cells
extracted from them without any stimulation, with α-IgM stimulation and without and
with CsA. The results show a strong expression of NFATc1, even stronger than in
stimulated B cells from WT mice. In both WT and caNFATc1/αA x mb1cre mice the
expression was abolished by CsA (Fig. 4.1).
Figure 4.1: Expression of NFATc1 in splenic B-cells
from caNFATc1/αA x mb1cre mice
WB using total protein extract from splenic B cells from
caNFATc1/αA x mb1cre and WT mice. The cells were
either left unstimulated or stimulated with α-IgM for 24
hours. The last lane shows protein extract from cells
stimulated with α-IgM and also CsA was added.
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4.1.2. Increased numbers of splenic B cells in mice expressing a constitutive active
version of NFATc1 with a knocked out IRF4
In order to examine the results of constitutive activity of the NFATc1 and/or
the knock out of the IRF4 specifically in B cells, we used FACS analysis of the
surface markers of splenocytes to examine the relative numbers of B and T cells from
spleens of caNFATc1/αA x mb1cre, IRF4 f/f x mb1cre and caNFATc1/αA x IRF4 f/f x
mb1cre mice, in comparison to WT mice. The results showed no significant difference
in B-cell counts from spleens of the controls (WT) and mice with over-expression of a
constitutive active version of NFATc1 (caNFATc1/αA x mb1cre mice), or mice
lacking the Irf4 gene (IRF4 Ko mice). But the results showed a significant increase in
B-cells from spleens of mice with both over-expression of NFATc1 and inactivation of
the Irf4 gene (caNFATc1/αA x mb1cre x IRF4 Ko) (Fig. 4.2).
Figure 4.2: Lymphocytic counts using Flow cytometry.
Lymphocytes were isolated from spleens of WT, caNFATc1/αA x mb1cre, IRF4 f/f x mb1cre and
caNFATc1/αA x IRF4 f/f x mb1cre mice. The cells were stained against the surface marker B220 (B
cell marker) and CD3 (T cell marker). The B220 antibody was labeled with FITC (X axis) and CD3
with PE (Y axis). (A) FACS generated dot blots. (B) Diagram representing data from four
experiments.
4.1.3. Decreased AICD (Activation induced cell death) of B cells in IRF4 Knockout mice
and caNFATc1/αA x mb1cre x IRF4 Ko mice, compared to wild type mice
To explore the effect of NFATc1 and IRF4 on B cell survival, we
conducted annexin-V based apoptosis assays. In these experiments we observed a
Results 47
significant decrease in living cells from wild type mice when stimulated with α-IgM
in comparison to non stimulated cells. Also, there was a significant decrease in the
live cells from caNFATc1/αA x IRF4f/f x mb1cre and IRF4 Ko x mb1cre mice in
comparison to cells coming from WT mice. This was found to be more significant in
stimulated cells (AICD) than non stimulated cells.  However, there is no significant
difference between the number of living cells in Irf4Ko and caNFATc1/αA x IRF4f/f
x mb1cre mice in both cases of IgM stimulation or non stimulation (Fig. 4.3).
Figure 4.3: Activation Induced Cell Death (AICD) of splenic B-cells from caNFATc1/αA x
IRF4f/f x mb1cre and IRF4f/f x mb1cre mice, after 48 hour incubation
Isolated B cells from WT , IRF4 f/f x mb1cre and caNFATc1/αA x IRF4 f/f x mb1cre mice/; were
cultured with or without α-IgM for 48 hr. Cells were stained with Annexin-V (X axis) and propidium
iodide (PI, Y axis). (A) FACs generated dot blots for numbers of apoptotic/live cells. (B) Diagram
representing percentage of live cells from data of four experiments.
4.1.4. Increase in the proliferative capacity of the B cells from IRF4 knockout and
caNFATc1/αA x mb1cre x IRF4 Ko mice compared to wild type mice
Using CFSE staining and the Flowjo software we wanted to examine the
effect of NFATc1 and IRF4 on B cell proliferation. Data from these experiments
show that with stimulation by α-IgM and LPS; the numbers of cells going into
maximum number of division cycles are higher in caNFATc1/αA x IRF4f/f x mb1cre
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than IRF4f/f x mb1cre which are higher than the cells from wild type mice. With α-
CD40 stimulations, only the numbers of cells going into maximum number of
division cycles from caNFATc1/αA x IRF4f/f x mb1cre mice are significantly higher
than cells coming from both wild type and IRF4f/f x mb1cre (Fig. 4.4).
Figure 4.4: Proliferation studies of splenic B-cells from caNFATc1/αA x IRF4f/f x mb1cre and
IRF4f/f x mb1cre
Isolated B cells from WT, IRF4 f/f x mb1cre and caNFATc1/αA x IRF4 f/f x mb1cre were shortly
incubated with CFSE, then divided and cultured for 48h without stimulation.  The stimulations
included α-IgM (10µg/ml), with α-CD40 (5µg/ml) or LPS (10µg/ml). Using the Flowjo software,
analysis of the proliferation based on the CFSE dilution was done. (A)FACS generated histograms
demonstrating the pattern of proliferation of cells. (B) Quantative representation of data from three
experiments of CFSE-based proliferation analysis.
4.1.5. In B cells the expression of RelB is affected by defects in IRF4.
To investigate the effect of the IRF4 on the NF-κB factors, the expression
of Rel-B in B cells using WB was investigated. The experiments showed that upon
stimulations (α-IgM, α-CD40 and LPS) for 48h, Rel-B expression was lower in
IRF4f/f x mb1cre mice than in B-cells from wild type mice (Fig. 4.5).
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Figure 4.5: Expression of Rel-B in B-cells from IRF4Ko.
(A) The WB of the NFATc1 using whole protein extracts from splenic B cells. (B) Quantative
representation of Western blot based on band intensity measurement by fusion software.
4.2. The NFAT - NF-κB connection
4.2.1. Increase in BCR-induced AICD in B cells lacking NFATc1 and/or c-Rel
To explore the interaction between the NF-κB and NFAT pathways on B
cell survival, we determined by FACS using annexin-V the apoptosis rate of B cells
from spleens of c-RelKo, NFATc1f/f x mb1cre and NFATc1f/f x c-RelKo x mb1cre
mice, upon stimulation with α-IgM, α-CD40 and LPS for 48h. Our data did not show
a significant change in live cells in the population of splenic B-cells for all gene-
deficient mice (NFATc1 knock-out, c-Rel Knock-out and double knock-out) after
stimulations with LPS or α-CD40, in comparison to splenic cells B cells from wild
type mice and in comparison to the same type of B cells without stimulation.
However, only with α-IgM there was a decrease in live cells in all gene-deficient
mice in comparison to the unstimulated cells. Also, the B cells coming from double
knock-out mice showed a significant decrease in the live cells, in comparison to the
WT cells upon α-IgM stimulation (Fig. 4.6).
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Figure 4.6: Activation Induced Cell Death (AICD) in splenic B-cells after incubation for 48
hours in c-RelKo mice.
Isolated B cells from WT, c-RelKo, NFATc1f/f x mb1cre and NFATc1f/f x c-RelKo x mb1cre mice
were cultured with or without stimulation for 48h. Stimulations included α-IgM (10μg/ml), α-CD40
(5μg/ml) and LPS (10μg/ml). Cells were stained with annexin-V (X axis) and propidium iodide (PI, Y
axis). (A) Diagram representing percentage of live cells from data of four experiments. (B) FACs
generated dot blots for numbers of live cells from one of the experiments.
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4.2.2. More defects in proliferation of DKO B cells than of B cells from single
NFATc1 knock-out and c-Rel knock-out
In order to investigate the role of NF-κB and NFAT pathways on B cell
proliferation, we conducted FACS-based analysis of CFSE staining and dilution for
determining the proliferation of splenic B cells from c-RelKo, NFATc1f/f x mb1cre and
NFATc1f/f x c-RelKo x mb1cre, in comparison to B cells from WT mice. These in
vitro experiments showed that B cells from NFATc1 knock-out and c-Rel Knock-out
mice exhibit a proliferative defect towards various stimulation schemes (α-IgM, LPS
and α-CD40), in comparison to B cells from WT mice. This defect is even more
significant in B cells coming from Double knock-out mice, deficient for both c-Rel and
NFATc1 (Fig. 4.7).
Figure 4.7: Proliferation studies of
splenic B-cells deficient for NFATc1, c-
Rel or both factors (DKO).
B cells isolated from WT, c-Rel Ko,
NFATc1f/f x mb1cre and NFATc1f/f x c-
Rel Ko x mb1cre mice were shortly
incubated with CFSE, then divided and
cultured without stimulation, with α-IgM
for 48h, with α-CD40 for 72h or with LPS
for 72h. Using Flowjo we analyzed the
proliferation based on the CFSE dilution.
(A) FACs generated histograms
demonstrating the proliferation of cells.
The grey overlay is the non-proliferating
unstimulated cells (B) Quantative
representation of data from three
experiments of CFSE based proliferation
analysis.
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4.2.3. In B cells the expression of RelB is affected by NFATc1 expression
To investigate the effect of NFATc1on the expression of NF-κB members we
performed several WBs. We used protein extracts of B cells from NFATc1f/f x
CD23cre, caNFATc1/αA x CD23cre and NFATc1f/f x caNFATc1/αA x CD23cre mice.
The WBs showed that most of the members of NF-κB remained unaffected by changes
in the NFATc1 levels in B cells (Results not shown). However, in figure 4.8 we show
that Rel-B (a member of the non-canonical NF-κB pathway) was affected.  We
demonstrate that all the α-IgM stimulated samples (last four columns) show a higher
expression of Rel-B than the non-stimulated samples (first four columns). With α-IgM
stimulation for 48 h, the expression from the NFATc1f/f x CD23cre B cells (6th
column) are higher than the wild type (5th column) and the expression from the
NFATc1f/f x caNFATc1/αA x CD23cre (7th column) are even higher than the
NFATc1f/f x CD23cre. However, the expression in B cells from caNFATc1/αA x
CD23cre (last column) is surprisingly lower than all other samples (5th, 6th and 7th).
Figure 4.8: Expression of Rel-B in B-cells from NFATc1f/f x CD23cre, caNFATc1 xCD23cre and
caNFATc1 x NFATc1f/f x CD23cre mice
(A) Quantative representation of the Western blot in (A) based on band intensity measurement by
fusion software. (B) Western blot showing the expression of Rel-B in whole protein extracts from
splenic B-cells from NFATc1f/f x CD23cre (NFATc1 is knocked out in splenic B cells),
caNFATc1/αA x CD23cre (NFATc1/αA is over expressed in splenic B cells) and NFATc1f/f x
caNFATc1/αA x CD23cre (NFATc1 is knocked and NFATc1/αA is over expressed in B cells) mice.
4.2.4. In B cells the expression of NFATc1 is affected by c-Rel ablation.
To investigate the effect of c-Rel ablation (a member of the canonical NF-κB
pathway) on the expression of NFATc1 we performed several WBs. We used
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protein extracted from B cells from wild type and c-Rel knock-out mice. As Figure
4.9 demonstrates, the WBs showed that α-IgM-induced expression of NFATc1 is
strongly decreased in B-cells from c-Rel Knock-out mice, in comparison to B cells
from wild type mice as early as 2 hours stimulation. This defect is even more evident
over longer stimulation periods (4-24 hours).
Figure 4.9: Expression of NFATc1 in B cells from c-Rel Knock-out mice.
Western blot using whole protein extracts from splenic B-cells. Cells were either left unstimulated
(0h) or stimulated for 2-24h by 10µg/ml α-IgM or by 10µg/ml α-IgM for 30min followed by 5 µg/ml
α-CD40 for 24h.
In these EMSAs (‘Electrophoretic Mobility Shift Assays’) we analyzed the
DNA binding of NFAT and NF-κB factors in primary splenic B cells from wild type
and c-Rel-deficient mice. Figure 4.10.A illustrates that the generation of NF-κB
complexes in the absence of c-Rel was strongly impaired (lanes 9-12), in
comparison to their formation in wild type extracts (lanes 1-8). More precisely, after
2 h stimulation by α-IgM a strong defect in NF-κB complex formation can be seen in
wild type extracts (lanes 3 and 6). Under the same stimulation conditions no
complex formation can be observed for nuclear protein extractions from B cells of c-
Rel-deficient mice (lanes 11 and 12). Interestingly, a very similar effect of c-Rel
ablation was observed for the appearance of nuclear NFAT complexes (see lanes 23
and 24). In agreement with the western blot data (from figure 19) these finding
suggests that c-Rel exerts a strong effect on the expression and nuclear localization
of NFAT factors.
In super-shift EMSA experiments we analyzed which NF-kB and NFAT
proteins are affected by the missing c-Rel. The data of the super-shift EMSA
experiment (figure 4.10.B) show that the α-IgM induction of NFATc1 is strongly
Results 54
affected by the c-Rel ablation. In Figure 4.10.C a replication of the same experiment
that emphasizes on the same results, where the NFAT complexes can be seen in the
after 2 hours in the WT (lane 2) and a further supershift of the complexes that show
that NFATc1(lane 3) is more expressed than NFATc2 (lane 4). On the other hand,
there is lack of the NFAT complexes formation and subsequently the shifted
complexes in lanes of the c-Rel knock-out (lanes 5-8). Using the κB probe we could
clearly see that the c-Rel is not part of the complex (lane 15) and the main
contributors are p50, p65 and RelB (lanes 13, 14 and 16) and therefore, the absence
of the c-Rell is the main reason of the NFAT complex formation defects.
Figure 4.10: EMSA and super shift EMSA for detecting NFAT and NF-κB factors in primary
splenic B cells from wild type and c-Rel-deficient mice
WT: protein extracts from wild type mice B-cells , c-Rel-/-: protein extracts from c-Rel deficient mice
B-cells. St.: the type of stimulation used. h: duration of stimulation. c1: NFATc1 antibody. c2:
NFATc2 antibody. Splenic B-cells were either left untreated or treated by α-IgM, α-CD40 or LPS.
The stimulations was for variable time durations as indicated. Cells were harvested, then nuclear
proteins were extracted. The protein content of extracts was measured, and equal amounts of nuclear
proteins were incubated – under EMSA conditions – with a radioactively labeled double-stranded
probe of approximately 25 bp. Upon incubation of probe with 2.5 g nuclear protein for 30 min on
ice, the incubation mixture was loaded on a 6% non-denaturing polyacrylamide gel and fractionated
for about 3 hrs. After the run, the gel was dried on a gel dryer and exposed overnight (or longer) at -
70° C. A and B is from one experiment, where A is the EMSA and B is the supershift from sample 18
and sample 24 of A. C is an independent experiment with the EMSA and supershift EMSA together.
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In the results from these experiments (Fig. 4.11) we could see that the c-Rel
Knock-out mice has a defect of the expression of NFATc as early as the RNA
synthesis with different stimulation durations (0.5, 1, 6, and 24 hours) in comparison
to the RNA synthesis in case of the wild type mice. This is all in agreement with the
EMSA experiments (Fig. 4.10) and the WB results (Fig. 4.9) previously presented.
Figure 4.11: RT-PCR assay showing the generation of NFATc1 RNA from p1 in primary
splenic B cells from wild type and c-Rel-deficient mice
Experiments were done three times and in each time a triplicate of the sample were used for the
measurements. Stimulations used were 0.5, 1, 6, and 24 hours.
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4.2.5. Plasma cells development is impaired in mice with c-Rel defect
To identify how the c-Rel abolishment may interfere with the B cell
development we performed extracted B cells from spleens of WT and c-Rel knock-
out mice. Stimulated them for 48 hours with different stimuli as shown in figure 4.12
and examined the formation of plasma cells using FACs and surface marker staining
of B220 and CD138. The results showed that wild type mice all stimulations
produce increase in plasma cell numbers that is higher from the non stimulated
samples and the corresponding samples from the c-Rel Ko mice (Fig. 4.12).
Figure 4.12: Plasma cells in c-Rel Ko mice.
Quantative representation of percentage of plasma cells in splenic B-cells from c-Rel Ko mice after
different stimulation schemes. Plasma cells were identified by the surface expression of B220 and
CD138.
4.3. IMQ- induced skin inflammation - a mouse model for human psoriasis
Cyclosporin A (CsA) application is one of the treatments that is included in several
psoriasis management protocols. It was found that CsA modulates the immune reaction that
is supposed to be part of the pathogenesis of psoriasis. Also, CsA is a known inhibitor of
NFATc activation pathway by inhibiting the dephosphorylation of cytoplasmic NFATc by
blocking the activity of the Ca++-dependent Ser/Thr-phosphatases calcinurine (CN). To
investigate the link between psoriasis and NFAT in general and NFAT in B cells in
particular the following experiments were performed.
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4.3.1. IMQ induces a psoriasis-like inflammation in mice
To examine how IMQ does affect the mouse skin we applied IMQ (or a
vehicle in the control group) to the shaved backs of the WT mice for 7 successive
days. We observed a clear cut inflammation that started after 3 days and reached
maximum after 6 days that shows many features similar to human psoriasis. By
naked eye we observed erythema, scaling and thickening (Fig. 4.13.A), That we
analyzed according to the modified PASI scoring system (Fig. 4.13.B). H.&E.
stainings and microscopy examinations confirmed the characteristics of human
psoriasis in skin sections including parakeratosis, acanthosis and elongation   of   the
dermal   papillae in the IMQ-treated mouse skin (Fig. 4.13.C: 2), in comparison to
the apparently healthy skin in the vehicle-treated mouse skin (Fig. 4.13.C: 1).
Figure 4.13: IMQ-induced psoriasis-like inflammation in WT mice.
(A) Naked eye picture examination (NE) of psoriasis like skin reaction (erythema, scaling and
thickening) in wild type mice treated with IMQ -2- compared to a healthy looking skin in WT mice
treated with a vehicle -1-. (B) modified psoriasis area and severity Index (mPASI). (C) Light
microscopy examination (LM) of skin sections from mice after 7 days of treatment stained with H.
&E. showing parakeratosis (retention of nuclei in the stratum corneum), acanthosis (thikening of the
stratum basale and spinosum) and elongation of   the   dermal   papillae in the IMQ-treated -2- in
comparison to the vehicle-treated -1-.
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4.3.2. The IMQ-induced psoriasis is attenuated upon NFATc1 ablation in B cells
To see if the ablation of NFATc1 from B cells may have an effect on the
clinical picture of the IMQ-induced psoriasis in mice, we used IMQ on NFATc1f/f x
mb1cre mice and WT mice in the same way as in the previous experiment. By naked
eye examination the wild type mouse showed the same picture, mPASI score and H.
& E. stainings as the in previous experiment (Fig. 4.14.A: 2 , Fig. 4.14.B: blue and
Fig. 4.14.C: 2) of the psoriasis-like inflammation. In contrast, the clinical picture of
NFATc1f/f x mb1cre mice showed minor -if any- alterations, in comparison WT
mice (Fig. 4.14.A: 1 , Fig. 4.14.B: red and Fig. 4.14.C: 1).
Figure 4.14: IMQ induced psoriasis-like inflammation in WT and NFATc1f/f x mb1cre mice.
(A) Naked eye picture examination (NE) of psoriasis like skin reaction (erythema, scaling and
thickening) in wild type mice treated with IMQ -2- compared to a healthy looking skin in NFATc1f/f
x mb1cre mice treated also with IMQ -1-. (B) modified psoriasis area and severity Index (mPASI).
(C) light microscopy examination (LM) of skin sections from mice after 9 days of treatment stained
with H. &E. showing parakeratosis (retention of nuclei in the stratum corneum), acanthosis (thikening
of the stratum basale and spinosum) and elongation of   the   dermal   papillae.
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4.3.3. The IMQ-induced psoriasis is more severe in mice lacking B cells and the
inflammation decreases upon adoptive transfer of B cells from WT mice and is
nearly abolished upon transfer of B cells lacking NFATc1
To further investigate the role of B cells in psoriasis-like autoimmune
pathogenesis, we explored the effect of IMQ on homozygous mb1cre mice. These
mice bear two mutated mb1/Cd79a alleles that code for the α-chain of BCR. Due to
this signaling defect these mice posses very low B cell numbers in periphery. Our
first set of experiments showed that IMQ application on homozygous mb1cre mice
produce an exaggerated psoriasis-like inflammation seen by NE (Fig. 4.15.A) that
was confirmed by modified PASI scoring (Fig. 4.15.B) and H.&E. staining (Fig.
4.15.C), in comparison to the IMQ-induced psoriasis-like inflammation in WT mice.
Moreover, our second set of experiments showed that the adoptive transfer of B cells
from WT mice 5 days before the IMQ application decreased the psoriasis-like
inflammation. More interestingly, adoptive transfer using B cells lacking NFATc1
(from NFATc1f/f x mb1cre mice) lead to minimal inflammation (Fig. 4.15.D and .E)
indicating an important role of NFATc1 expression in B cells for the generation of
psoriasis-like inflammation.
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Figure 4.15: IMQ induced psoriasis-like inflammation in mice bearing two inactivated
mb1/Cd79a alleles (mb1cre homozygous)
(A) Naked eye picture examination (NE) of psoriasis like skin reaction (erythema, scaling and
thickening) in wild type mice treated with IMQ -2- compared to a healthy looking skin in WT mice
treated with a vehicle -1-, compared to severe skin inflammation and scaling  in mb1cre homozygous
mice treated with IMQ -3-. (B) modified Psoriasis Area and Severity Index (mPASI). (C) Light
microscopy examination (LM) of skin sections from mice after 9 days of treatment stained with H.
&E. (D) -1- Naked eye examination in skin of mb1cre homozygous mice after induction of severe
psoriasis-like inflammation by IMQ. -2- B cells from WT mice were adoptively transferred to the
mb1cre homozygous mouse 5 days before the IMQ treatment. This mouse is showing less
inflammation. -3- B cells from NFATc1f/f x mb1cre mouse were adoptively transferred to the mb1cre
homozygous mouse 5 days before the IMQ treatment. This mouse is showing slight inflammation. (E)
modified Psoriasis Area and Severity Index (mPASI) of the (D) mice.
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4.3.4. Decreased Ig-class switch in IMQ-induced psoriasis-like inflammation in mice
with ablated NFATc1 in B cells
To investigate the B cell compartment changes that may have a role in the
differential response towards the IMQ-induced psoriasis-like inflammation, we
examined surface immunoglobulin expression in B cells using FACS. We found a
decrease in the B cells expressing IgG1 in mice with knocked-out NFATc1 in
comparison to B cells from WT mice (Fig. 4.16).
Figure 4.16: IgG1 expressing B cells from LN in IMQ induced psoriasis-like inflammation.
Mice back skin was shaved then were treated by IMQ or vehicle for 8 days. Spleenocytes where
isolated and stained for B220 (in FITC – horizontal axis) and IgG1 (in PE – vertical axis). (A) FACS
generated dot blot demonstrating the gating protocol on the B cells using B220 and CD3 staining. B
cells are B220+CD3- (B) FACS generated histograms demonstrating the percentage of IgG1+ B cells.
The solid grey histogram is an overlay of an isotype control. (C) Quantative representation of data
from four different experiments.
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4.3.5. Increased numbers of Bregs in IMQ-induced psoriasis-like inflammation in
mice with ablated NFATc1 in B cells
To investigate the role of Bregs in the IMQ-induced psoriasis-like
inflammation, we used surface staining of B cells to analyze their numbers in  the
NFATc1f/f x mb1cre mice. After gating on B cells (B220+) the percentage of Bregs
(CD5+ CD1dhi) were found to be significantly increased in NFATc1f/f x mb1cre
mice, compared to WT mice both with the vehicle or the IMQ application. With
IMQ application the numbers of Bregs significantly increase in both WT and
NFATc1f/f x mb1cre mice (Fig. 4.17).
Figure 4.17: Bregs in LN in IMQ-induced psoriasis-like inflammation.
Mice back skin was shaved then were treated by IMQ or vehicle for 8 days. Spleenocytes where
extracted and stained for B220 (FITC), CD1d (PE) and CD5 (PerCP). After gating on B220+ cells (B
cells), cells were blotted using CD1d (horizontal axis) and CD5 (vertical axis). (A) FACS generated
dot blot demonstrating the numbers or Bregs. The Bregs are the CD5+ CD1dhi cells (top right gate of
each blot). (B) Bar figure representing data from four different experiments.
4.3.6. Increased IL-10 expression in Bregs in IMQ-induced psoriasis in mice with
ablated NFATc1 in B cells
To investigate the actual effect of the Bregs that is increased in NFATc1f/f x
mb1cre mice in response to the IMQ-treatments, we used intracellular FACS
staining to analyze the expression of IL-10 in Bregs cells. Our data showed a
significant increase in IL-10 expression in NFATc1f/f x mb1cre mice, compared the
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IL-10 expression of the Bregs cells from WT with vehicle application to the mice.
Additionally, this significance is increased in response to IMQ treatment (Fig. 4.18)
Figure 4.18: IL-10 expression from Bregs in LN in IMQ induced psoriasis-like inflammation.
Mice back skin was shaved, then were treated by IMQ or vehicle for 8 days. Spleenocytes where
isolated and stained for B220  (FITC), CD1d (PE), CD5 (PerCP) and IL-10 (APC). After gating on
B220+ cells (B cells), cells were blotted using CD1d and CD5. After that, we re-gated on Bregs
(CD5+ CD1dhi cells). (A) FACS generated histogram of the IL-10 expression showing the
expression of IL10. The solid grey histogram is an overlay of an isotype control. (B) Bar figure
representing data from four different experiments.
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5. Discussion
5.1. Expression of a constitutive active version of NFATc1 (caNFATc1/αA) with ablated
IRF4 in B cells from mice.
The NFAT factors NFATc1, NFATc2 and NFATc3 are expressed in immune
cells, especially B and T cells, and regulate their development and function through
regulating gene expression. The Ca++-calcineurin axis in general and the NFATc
factors in particular are induced through the immune receptors and regulate
transcriptional states of important genes of lymphokine production (IL-2) (Nguyen
et al., 2010), proliferation (CDK4) (Baksh et al., 2002) and apoptosis (Fas ligand,
FASLG) (Lee et al., 2002). Retroviral tagging experiments provided data that proves
that most of the oncogenic virus binding sites lies in close vicinity of the murine
NFATc1 promoter indicating that its part of the modulatory effect of the virus in the
infected cell (Serfling et al., 2006a).
To test the effect of over expression of NFATc1/αA on B cells we generated
the caNFATc1/αA x mb1cre mice which over express the NFATc1/αA in B cells
and we proved that the expression of the NFATc1 is high even without any
stimulation (Fig. 4.1). We also generated an IRF4 f/f x mb1cre mouse to be crossed
with the caNFATc1/αA x mb1cre  producing an effect that includes disruption of the
late stages of B cell development as occurring in lymphoid tumors (Calado et al.,
2010). Our experiments showed that the isolated effect of constitutive NFAtc1 or
knocked out IRF4 does not cause any effect in the development and hence the
numbers of B cells. However, we found increased numbers of splenic B cells in mice
with both constitutive NFATc1 and a knocked out IRF4 (Fig. 4.2), indicating that a
‘double hit’ in factors affecting B cell activation (NFATc1 in this case) and late B
cell differentiation (IRF4 in this case) is needed to alter the development of the B
cells and lead to increase in their numbers above normal. Also there was increased
stimulation induced proliferation of the B cells from either the mice with the missing
IRF4 alone or together with the over expressed NFATc1 pointing to a state of
uncontrolled proliferation (Fig. 4.4). This is similar to previous cell line transfection
studies which revealed that over-expression of  NFATc1/αA leads to increased
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proliferation and cell transformation marking it as a potential oncogene in
lymphocytes (Robbs et al., 2008). Also in line with Pham's group, which proved that
NFATc1 recruit chromatin remodeling complexes to targeted gene promoters
leading to alteration of gene expression in DLBCL cells (diffuse large B cell
lymphoma) (Pham et al., 2010). Nevertheless, in our experiments the cell survival of
the transgenic mice was less than the wild type mice (Fig. 4.3), implying that
NFATc1 over expression and/or IRF4 Knock out may not predispose to
tumorogenesis in a direct explicit mechanism. However, the overall picture of a
‘double hit’ effect could be related to the work from Rajewsky's group that addresses
the NF-κB over-expression together with the BLIMP-1 disruption (Calado et al.,
2010). Putting in mind the data of Lu et al. which suggest that IRF4 controls the
expression of BLIMP-1, we can assume that the effect of IRF4 knock out will have a
similar effect as the BLIMP-1 (Lu, 2008). The provisional experiments to identify
the molecular interaction of IRF4 that leads to such changes in B cell physiology
showed affection of the Rel-B of the non canonical NF-κB pathway.
5.2. The NFAT - NF-κB connection
5.2.1. Increase in BCR-induced AICD in B cells lacking NFATc1 and c-Rel
Our data showed that ablation of NFATc1 or c-Rel alone in B cells does not
impair apoptosis. However, the BCR induced AICD (upon α-IgM stimulation) is
significantly increased in DKO B cells, in comparison to WT or to single knock-out
of NFATc1 or c-Rel (Fig. 4.6). This may point that defects in either single members
of the pathway does not affect cell survival. Nevertheless, the activation of the BCR
signals in the absence of NFATc1 or c-Rel impairs cell survival by inducing more
AICD especially with defects in both pathways (DKO mice). That may indicate that
both of these members play a co-operative role in B cell survival. This is in
accordance with previous results from our laboratory that states that the BCR
induced AICD is increased in NFATc1 knock-out B cells (Bhattacharyya et al.,
2011), but this increase is dependent on the strength of the α-IgM mediated BCR
signals. High concentrations of α-IgM, such as 10µg/ml and more, could 'overplay'
the defect in the BCR-mediated AICD. The c-Rel knock out effect is also fitting well
with the findings of Gerondakis that proved that A1 induction through c-Rel signals
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protect B cells from BCR-induced AICD (Grumont et al., 1999). The absence of
such profound effect with the stimulation of other B cell receptors (Toll-like receptor
or CD40) is probably due to the intact functions of other members of the NF-κB
family, as the original producers of the c-Rel Knock-out mice states (Kontgen et al.,
1995). Our other results show that other members of the canonical pathway are
intact and remained unchanged in expression in NFATc1 knock-out mice
(unbuplished data, Serfling et al). Also, our results could be understood in the light
of data demonstrating that the molecular interaction of c-Rel with Bim (Bcl-2
member) leading to neutralization of specific phosphorylation pro-apoptotic signals
which support B cell survival (Banerjee et al., 2008).
5.2.2. More defects in proliferation of DKO B cells than of B cells from single
NFATc1 knock-out and c-Rel knock-out
Our experiments showed a cumulative negative effect in proliferation of B
cells from the double knock out of NFATc1 and c-Rel, compared to the B cells from
single knock-out of NFATc1 or c-Rel (Fig. 4.7). The proliferative defect in NFATc1
deficient mice is in accordance to previous results of our laboratory (Bhattacharyya
et al., 2011). These results may be explained by the interaction of NFATc1 with
STAT-3 as previously proposed by Kundumani-Sridharan (Kundumani-Sridharan et
al., 2012). On the other hand, the proliferative defect of B cells from c-Rel knock-
out mice goes well with other data from the Gerondakis group (Kontgen et al.,
1995). It could be accounted by the effect on Cyclin E and Bcl-xL explained by
Cheng (Cheng et al., 2003). Taken together these data with our findings indicate
that the cumulative effect observed from the DKO B cells is due to a complimentary
effect of both TFs on B cell proliferation.
5.2.3. In B cells the expression of RelB is affected by NFATc1 expression whereas the
expression of NFATc1 is affected by c-Rel.
The link between the members of NFAT and NF-κB families has always
been rooted to the RHD that represents the DNA binding domain of both factors.
RHD mediates most of the NFAT interactions with the DNA binding motifs of both
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transcription factors. In our hands (Fig. 4.8) we could show that RelB expression in
B cells is increased in mice lacking NFATc1 in B cells (NFATc1f/f x CD23cre mice)
and decreased in the mice with the overexpressed NFATc1 (caNFATc1/αA x
CD23cre mice). This inverse connection between NFATc1 expression and RelB
expression points to an opposing interplay between the NFAT pathway and the non-
canonical NF-κB pathway. However, this observation is not supported by data
showing the inhibition of NFAT-affected gene expression using VIVIT and not
genes affected by NF-κB (Aramburu et al., 1999). But it might be in line with data
from the group of Cai et al. who proved that activation of NFAT and NF-κB
dependens on each other (Cai et al., 2011).
On the other hand, our WB experiments showed that at the protein level the
expression of NFATc1 is defective in c-Rel Knock-out mice (Fig. 4.9). In addition,
the RNA transcripts of P1-directed NFATc1/α were also severely impaired in c-Rel
knock-out mice, as shown in our RT-PCR experiments (Fig. 4.11). Moreover, the
EMSA and super shift EMSA data support these findings by the lack of NFAT
complexes in nucleoprotein extracts of B cells from c-Rel knock-out mice after 2
hours of B cell stimulation (Fig. 4.10). This points to a role of c-Rel (as a member of
the canonical NF-κB pathway) in sustaining NFATc1 expression. This finding -
together with the previously suggested RelB role- indicate a double edged
relationship of the NFAT pathway with the two sides of the NF-κB pathway (i.e. the
canonical and the non-canonical pathways). This is supported by research findings
from cancer fields that suggests a close association between NFAT and NF-κB
regarding co-expression and constitutive expression. One of these findings comes
from studies of pancereatic cancer cells. Kalthoff and colleagues showed that both
NFAT and NF-κB factors are crucial for tumor development and chemotherapy
resistance in pancreatic cancer (Arlt et al., 2012). Furthermore, it is worth to notice
that DNA binding motifs that are bound by both NF-κB and NFAT members are
found in the promoters of many inducible genes (eg. Nfatc1 P1 promoter) and are
also considered as optimal c-Rel binding sites.  Accordingly, we could infer that
both c-Rel or NFATc affect the fate of peripheral B cells through theses motifs
(Kunsch et al., 1992).
Discussion 68
Two studies report on a direct interaction between NF-κB and NFAT
proteins under over-expression conditions. One of these investigates deals with the
CD154/CD40LG promoter in human LBCL lymphoma cells. The other investigates
the function of NFATc1 in neonatal cardiomyocytes. In both of them, they use
super-shift EMSA to suggest a co-operative hetero-dimer formation between
NFATc1 and c-Rel. Conversely, they do not show any prove of interaction between
NFAT and NF-κB without over-expression (physiological conditions) and they do
not investigate how the protein-protein interactions between the two factors affect
their DNA binding and, thereby, the activity of genes.
My data on the role of c-Rel on NFATc1 expresion (shown in figures 4.8,
4.9, 4.10 and 4.11) and other data from our group (not shown here) indicate that the
induction of NFATc1 is supported by c-Rel expression. c-Rel binds to the P1
promoter of Nfatc1 in which two composite κB/NFAT sites for the binding of both
c-Rel/p50 and NFATc1 are situated. The data propose that according to the
predominating levels of these factors during physiological or pathological conditions
(eg. cancer), they bound independently to the composite κB/NFAT binding sites
found in the promoters of many inducible genes.
5.2.4. Plasma cells development is impaired in mice with c-Rel defect
Our flow-cytometry analysis of B cell surface markers showed a defect in B
cell development towards plasma cells in c-Rel knock-out mice (Fig. 4.12). This is
consistent with the results of Kontgen et al. who showed a defect in antibody
production in B cells from c-Rel knock-out mice (Kontgen et al., 1995). The work of
other laboratories confirmed that c-Rel activation is important for the generation of
GC B cells and plasma cells (Klein and Dalla-Favera, 2008).
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5.3. IMQ-induced skin inflammation - a mouse model for human psoriasis
5.3.1. IMQ induces a psoriasis-like inflammation in mice
The development of inflammation in the skin of mice following the
application of IMQ was first reported by Gilliet in 2004. The study concluded the
important role of innate immunity in the development of a psoriasis-like
inflammation (Gilliet et al., 2004). In order to test the model, we applied IMQ in
Aldara creme (or a vehicle in the control group) to the shaved backs of WT mice for
7 successive days, and observed a clear cut inflammation that started after 3 days
and reached maximum after 6 days. The inflammatory reaction was very similar to
psoriasis by naked eye inspection: erythema, scaling and thickeningof the skin was
observed (Fig. 4.13.A ). We analyzed these alterations according to the modified
PASI scoring system (Fig. 4.13.B). H.&E. staining and microscope examination
confirmed the characteristics of the psoriasis generation in skin sections, including
parakeratosis, acanthosis and elongation   of   the   dermal   papillae (Fig. 4.13.C).
This is in accordance to previous results of the Burkhard Becher group. However,
these sceintists investigated the pathogenesis of inflamation from the T cells side and
found that IL17 in the psoriasis-like inflamation does not come only from Th17 cells
but also from Rorγt+ and γδ T cells (Pantelyushin et al., 2012).
5.3.2. The IMQ-induced psoriasis is attenuated upon NFATc1 ablation in B cells
The treatment regimens of psoriasis included cyclosporin A application, as
early as the autoimmune background of the disease was recognized. Cyclosporin A
inhibits the immune reaction through suppression of the Ca++-calcinurine pathway.
Because NFAT is activated through signals of the Ca++-calcinurine pathway upon
de-phosphorylation by the phosphatase calcinurine, we wanted to investigate the
probability of NFAT involvement in the IMQ-induced psoriasis-like inflammation.
When we used IMQ application on NFATc1f/f x mb1cre mice, we found a dramatic
decrease in the psoriasis-like inflammation, in comparison to WT mice. This clearly
points that NFATc1 is part of the signaling pathway that contributes to psoriasis
development. Additionally, it also points that B cells are important in the protection
from the psoriasis as NFATc1 in these mice was missing only in B cells (Fig. 4.14).
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This is well understood in the light of the various data that incorporate NFAT with
most of lymphocyte functions (Serfling et al., 2007). On their work on the CNS, the
laboratory of Lodygin et al. presented data that considered NFAT activation as a
crucial initiating step in autoimmunity (Lodygin et al., 2013). Moreover, it was
suggested that NFATc1 is important in regulating the proliferation and
differentiation of keratinocytes, based on its expression in normal and pathogenic
human keratinocytes (Al-Daraji et al., 2009). However, some data presented by
Ghosh et al. seem to disagree, indicating that hyperactive NFAT maybe a ‘muffler’
for development of the murine autoimmune encephalomyelitis. These authors are
actually describing a picture for the T cell compartment and incorporating a status of
increased IL-10 expression from CD4 T cells (Ghosh et al., 2010).
5.3.3. The IMQ-induced psoriasis is more severe in mice lacking B cells and the
inflammation decreases upon adoptive transfer of B cells from WT mice and is
nearly abolished upon transfer of B cells lacking NFATc1
In order to delineate the actual role of B cell involvement in the IMQ-
induced psoriasis-like inflammation we used mb1cre homozygous mice which due
to the inactivation of the BCR-α-chain have a minimal number of B cells. With IMQ
application on these mice we observed an exaggerated psoriasis-like inflammation
by naked eye examination (Fig. 4.15.A). This is also reflected on scores using the
modified PASI scoring system (Fig. 4.15.B). The H.&E. stained skin sections
showed a severe picture of hyperproliferative inflammation (Fig. 4.15.C).
Moreover, the adoptive transfer of B cells from WT mice 5 days before the IMQ
application decreased psoriasis-like inflammation, but more interestingly, using B
cells lacking NFATc1 (from NFATc1f/f x mb1cre mice) lead to a less profound
inflammation (Fig. 4.15.D and .E). This shows that the ablation of NFATc1 in B
cells is important for protection from IMQ-induced psoriasis-like inflammation. The
results of Sato's group agree with our view of the importance of B cells in psoriasis.
They used CD19-/- mice, another model of B cell-deficiency in mice. They showed a
similar increase in the severity of the IMQ-induced psoriasis-like inflammation as in
our mb1-cre homozygous mouse model (Yanaba et al., 2013).
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5.3.4. Decreased class switching in IMQ-induced psoriasis-like inflammation in mice
with ablated NFATc1 in B cells
To examine the effect of the lack of NFATc1 in B cells that lead to the
dampening effect on IMQ-induced psoriasis-like inflammation we studied the
surface immunoglobulin expression in B cells using FACS. We found a decrease in
the B cells expressing IgG1 in mice with knocked-out NFATc1 in comparison to B
cells from WT mice (Fig. 4.16), indicating a decrease in Ig class switch. The lack of
class switch points to less reactive B cells towards antigens. This may be in
agreement with results by Wang’s laboratory, that suggest that psoriasis pathogesis
is in part due to loss of tolerance towards self antigens which leads to reaction of the
immune cells towards RNA and DNA released from the keratinocytes in the process
of inflammation (Lande et al., 2007). In our NFATc1 x mb1cre mice, the decreased
reactivity of B cells due to less class switching leads to decrease in immune
reactions towards the keratinocytes, subsequently, to a decrease in psoriasis-like
inflammation in response to IMQ treatment. This is also compatible to data
published from our laboratory that show that in  NFATc1f/f x CD23-cre mice due to
the ablation of NFATc1, Ig class switch is strongly impaired upon T cell–
independent immune reactions (Bhattacharyya et al., 2011).
5.3.5. Increased numbers of Bregs in IMQ-induced psoriasis in mice with ablated
NFATc1 in B cells
Further analysis of the NFATc1f/f x mb1cre mice showed an increase
in the percentage of Bregs upon the IMQ treatment (Fig. 4.17). This indicates that
the inactivation of NFATc1 on bone marrow B cells leads to more Breg numbers in
periphery. Subsequently, this causes an inhibitory effect on the psoriasis-like
inflammation. This scenario fits well to the role of Bregs in psoriasis-like
inflammation proposed by Sato's group. Their data also identified IL-17 and IFN-γ
as central players in the Bregs mediated suppression of psoriasis (Yanaba et al.,
2013).
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5.3.6. Increased IL-10 expression from Bregs in IMQ-induced psoriasis in mice with
ablated NFATc1 in B cells
The analysis of Bregs showed more IL-10 expression by these cells in
NFATc1f/f x mb1cre mice, compared to the IL-10 expression of the same Bregs in
WT mice in response to IMQ treatment (Fig. 4.18). This suggests that IL-10 maybe
one of the players that mediates the B cell dampening effect on IMQ-induced
psoriasis-like inflammation in NFATc1f/f x mb1cre mice. These findings are in
agreement with previous data from our laboratory that could explain the role of
NFATc1 in murine autoimmune encephalomyelitis, a mouse model of human
multiple sclerosis (MS). NFATc1f/f x CD23-cre mice showed also decreased levels
of IL-10 from B cells which is concomitant with the less severe form of EAE in
these mice (Bhattacharyya et al., 2011). These EAE data are in agreement with the
data from Sato's group on the role of Bregs in the generation of psoriasis-like
inflammation (Yanaba et al., 2013).
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Ca2+ calcium
CARD9 caspase recruitment domain containing protein 9
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CCR2 chemokine receptor 2
CD cluster of differentiation
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Fig. figure
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for forward
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NES nuclear export signal
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R reverse
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rev reverse
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ROS reactive oxygen species
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sec (’’) seconds
SLP76 SH2-domain-containing leukocyte protein of 76 kDa
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SP single positive
Src c-Src tyrosine kinase
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STIM1 stromal interaction molecule 1
Syc spleen tyrosine kinase
TAD Transactivation domain
TAE Tris/Acetate/EDTA
TCR T-cell receptor
Th T-helper cell
TLR toll-like receptor
Tm melting temperature
TM transmembrane
TNF tumor necrosis factor
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Treg regulatory T-cell
µ micro-
U unit
-U upper
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wo (w/o) without
wt wild type
YPD yeast Extract Peptone Dextrose
ZAP-70 ζ-chain-associated protein kinase of 70 kDa
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